carnitine has been researched along with Diabetes Mellitus, Adult-Onset in 137 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Family history of obesity is the major predictor of obesity, and the metabolic abnormalities on amino acids, acylcarnitines, inflammation, insulin resistance, and NAFLD." | 9.27 | Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach. ( Caballero, AE; Duggirala, R; González-Chávez, A; Herrera-Rosas, A; Ibarra-González, I; León-Hernández, M; López-Alvarenga, JC; Mummidi, S; Romero-Ibarguengoitia, ME; Serratos-Canales, MF; Vadillo-Ortega, F, 2018) |
| "Acylcarnitines, fatty acid oxidation (FAO) intermediates, have been implicated in diet-induced insulin resistance and type 2 diabetes mellitus, as increased levels are found in obese insulin resistant humans." | 9.22 | Assessment of plasma acylcarnitines before and after weight loss in obese subjects. ( Ambler, GK; Hollak, CE; Houten, SM; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Schooneman, MG; Soeters, MR; Tan, CY; Vidal-Puig, A; Virtue, S, 2016) |
| " We evaluated the following parameters at baseline and after 3, 6, 9, and 12 months: body weight, body mass index (BMI), glycated hemoglobin (HbA(1c) ), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (Tg), adiponectin (ADN), leptin, tumor necrosis factor-α (TNF-α), vaspin, and high-sensitivity C-reactive protein (Hs-CRP)." | 9.15 | Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Maffioli, P; Palumbo, I; Randazzo, S, 2011) |
| "Sibutramine plus L-carnitine gave a faster improvement of lipid profile, insulin resistance parameters, glycemic control, and body weight compared to sibutramine." | 9.14 | Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "Our study wants to evaluate the effects of one year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and insulin resistance state in type 2 diabetic patients." | 9.14 | Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Maffioli, P; Palumbo, I; Randazzo, S, 2010) |
| "The present review provides an overview about data from both animal and human studies reporting effects of either carnitine supplementation or carnitine deficiency on parameters of glucose homeostasis and insulin sensitivity in order to establish the less well-recognized role of carnitine in regulating glucose homeostasis." | 8.88 | Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. ( Eder, K; Keller, J; Ringseis, R, 2012) |
| "Data on the functionalities of L-carnitine on obesity, diabetes, and as an ergogenic aid are summarized as follows: Obesity: Total lipid, triglyceride, and total protein increased during the 3T3-L1 cell differentiation." | 8.84 | Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. ( Cha, YS, 2008) |
| "Our results demonstrated that the biomarker panels consisted of specific amino acids and acylcarnitines which could reflect the metabolic variations among the different stages of diabetes and might be useful for the differential diagnosis of prediabetes, overt diabetes and diabetic complications." | 8.02 | Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications. ( Hu, R; Li, X; Li, Y; Liang, Y; Liu, Y; Xu, W, 2021) |
| "Carnitine orotate complex (Godex) has been shown to decrease glycated hemoglobin levels and improve steatosis in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease." | 8.02 | Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. ( Hong, JH; Lee, MK, 2021) |
| "Circulating acyl-carnitines (acyl-CNTs) are associated with insulin resistance (IR) and type 2 diabetes (T2D) in both rodents and humans." | 7.85 | Palmitoyl-carnitine production by blood cells associates with the concentration of circulating acyl-carnitines in healthy overweight women. ( Abate, N; Asghar, R; Brasier, AR; Camacho-Hughes, M; Chondronikola, M; Dillon, EL; Durham, WJ; Porter, C; Sheffield-Moore, M; Sidossis, L; Tuvdendorj, D; Volpi, E; Wu, Z; Zhang, X; Zhao, Y, 2017) |
| "In type 1 diabetes (T1D), type 2 diabetes (T2D) and metabolic syndrome (MetS), the associated complex metabolomic changes in the involvement of carnitine metabolism in total carnitine ester level has already been documented; here we extended the investigations to the individual acylcarnitines." | 7.79 | Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome. ( Bagosi, Z; Bene, J; Bujtor, Z; Gasztonyi, B; Márton, M; Melegh, B; Mohás, M; Oroszlán, T; Wittmann, I, 2013) |
| "Treatment with carnitine-orotate complex improves serum ALT and may improve hepatic steatosis as assessed by CT in patients with diabetes and NAFLD." | 6.80 | Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. ( Bae, JC; Cho, YY; Han, KA; Ju, YC; Lee, KW; Lee, MK; Lee, WJ; Lee, WY; Park, JY; Son, HS; Woo, JT; Yoon, KH, 2015) |
| "L-carnitine was given orally, 2 g twice daily, for 45 weeks." | 6.66 | [The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II]. ( Cantini, F; Digiesi, V; Palchetti, R, 1989) |
| "Carnitine was a major contributor to the pathway differences." | 5.51 | Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. ( Brantley, MA; Burgess, LG; Cherney, EF; Chocron, IM; Ferreira, AJ; Goodale, MP; Herren, DJ; Jones, DP; Law, JC; Ma, C; Mitchell, SL; Osborn, MP; Sumarriva, K; Uppal, K; Wang, Y; Warden, C, 2019) |
| "Insulin resistance (IR) predisposes to type 2 diabetes and cardiovascular disease but its causes are incompletely understood." | 5.48 | Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance. ( Ärnlöv, J; Berne, C; Broeckling, CD; Castillejo-Lopez, C; Cook, NL; Fall, T; Ganna, A; Giedraitis, V; Hetty, S; Ingelsson, E; Lind, L; Nowak, C; Prenni, JE; Salihovic, S; Shen, X; Sundström, J, 2018) |
| "Offspring of type 2 diabetes (T2D) patients have increased risk to develop diabetes, due to inherited genetic susceptibility that directly interferes with the individual adaption to environmental conditions." | 5.43 | Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT). ( Barsch, A; Fuchser, J; Haas, J; Knebel, B; Kotzka, J; Lange, S; Lehr, S; Mack, S; Müller-Wieland, D; Schiller, M; Zurek, G, 2016) |
| " We examined associations of weight loss diet-induced changes in a gut microbiota-related metabolite trimethylamine N-oxide (TMAO), and its precursors (choline and l-carnitine), with changes in bone mineral density (BMD) considering diabetes-related factors." | 5.30 | Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial. ( Bray, GA; Chen, Y; DiDonato, JA; Heianza, Y; LeBoff, MS; Li, X; Pei, X; Qi, L; Sacks, FM; Sun, D; Zhou, T, 2019) |
| " We examined associations of 6-month changes in blood metabolites (TMAO, choline, and l-carnitine) with improvements in body weight (BW), waist circumference (WC), body fat composition, fat distribution, and resting energy expenditure (REE)." | 5.27 | Changes in Gut Microbiota-Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial. ( Bray, GA; Heianza, Y; Qi, L; Sacks, FM; Smith, SR; Sun, D, 2018) |
| "Family history of obesity is the major predictor of obesity, and the metabolic abnormalities on amino acids, acylcarnitines, inflammation, insulin resistance, and NAFLD." | 5.27 | Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach. ( Caballero, AE; Duggirala, R; González-Chávez, A; Herrera-Rosas, A; Ibarra-González, I; León-Hernández, M; López-Alvarenga, JC; Mummidi, S; Romero-Ibarguengoitia, ME; Serratos-Canales, MF; Vadillo-Ortega, F, 2018) |
| "Acylcarnitines, fatty acid oxidation (FAO) intermediates, have been implicated in diet-induced insulin resistance and type 2 diabetes mellitus, as increased levels are found in obese insulin resistant humans." | 5.22 | Assessment of plasma acylcarnitines before and after weight loss in obese subjects. ( Ambler, GK; Hollak, CE; Houten, SM; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Schooneman, MG; Soeters, MR; Tan, CY; Vidal-Puig, A; Virtue, S, 2016) |
| " We evaluated the following parameters at baseline and after 3, 6, 9, and 12 months: body weight, body mass index (BMI), glycated hemoglobin (HbA(1c) ), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (Tg), adiponectin (ADN), leptin, tumor necrosis factor-α (TNF-α), vaspin, and high-sensitivity C-reactive protein (Hs-CRP)." | 5.15 | Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Maffioli, P; Palumbo, I; Randazzo, S, 2011) |
| "The aim of the study was to evaluate the effects of 12-month treatment with sibutramine plus L-carnitine compared with sibutramine alone on body weight, glycemic control, insulin resistance, and inflammatory state in type 2 diabetes mellitus patients." | 5.15 | Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2011) |
| "Sibutramine plus L-carnitine gave a faster improvement of lipid profile, insulin resistance parameters, glycemic control, and body weight compared to sibutramine." | 5.14 | Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "Our study wants to evaluate the effects of one year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and insulin resistance state in type 2 diabetic patients." | 5.14 | Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Maffioli, P; Palumbo, I; Randazzo, S, 2010) |
| "To investigate the synergic effect of propionyl L-carnitine (PLC) plus sildenafil in reducing monocyte oxidative activity and endothelial dysfunction markers in diabetic patients with erectile dysfunction (ED)." | 5.12 | Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. ( Buchetti, B; Fallarino, M; Gandini, L; Gatti, A; Jannini, EA; Lenti, L; Lenzi, A; Mandosi, E; Morano, S; Sensi, M; Tiberti, C, 2007) |
| "A previous study has demonstrated that L-carnitine reduces plasma lipoprotein(a) (Lp[a]) levels in patients with hypercholesterolemia." | 5.10 | The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R; Gaddi, A; Mugellini, A, 2003) |
| "L-carnitine constant infusion improves insulin sensitivity in insulin resistant diabetic patients; a significant effect on whole body insulin-mediated glucose uptake is also observed in normal subjects." | 5.09 | L-carnitine improves glucose disposal in type 2 diabetic patients. ( Benedetti, G; Capristo, E; De Gaetano, A; Gasbarrini, G; Giancaterini, A; Greco, AV; Mingrone, G, 1999) |
| " The increase in plasma acylcarnitines during exercise is not influenced by type 2 diabetes or obesity." | 4.95 | Do diabetes and obesity affect the metabolic response to exercise? ( Plomgaard, P; Weigert, C, 2017) |
| " Evidence suggests that branched-chain amino acids, acylcarnitines and aromatic amino acids may play an early role on insulin resistance, exposing defects on amino acid metabolism, β-oxidation, and tricarboxylic acid cycle." | 4.93 | Metabolomics in diabetes, a review. ( Aguilar-Salinas, CA; Cruz-Bautista, I; Del Bosque-Plata, L; Pallares-Méndez, R, 2016) |
| " Article search strategy included "Carnitine" OR "L-carnitine" AND "Diabetes -Mellitus" OR "Diabetes mellitus, type 2" OR "Noninsulindependent-diabetes mellitus"." | 4.89 | Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis. ( Burgos-Peláez, R; Calvo-Gracia, F; Cuerda-Compés, C; Luengo-Pérez, LM; Martínez-Faedo, C; Valero-Zanuy, MÁ; Vidal-Casariego, A, 2013) |
| "The present review provides an overview about data from both animal and human studies reporting effects of either carnitine supplementation or carnitine deficiency on parameters of glucose homeostasis and insulin sensitivity in order to establish the less well-recognized role of carnitine in regulating glucose homeostasis." | 4.88 | Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. ( Eder, K; Keller, J; Ringseis, R, 2012) |
| "Data on the functionalities of L-carnitine on obesity, diabetes, and as an ergogenic aid are summarized as follows: Obesity: Total lipid, triglyceride, and total protein increased during the 3T3-L1 cell differentiation." | 4.84 | Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid. ( Cha, YS, 2008) |
| " Specifically, we used genetic variants to predict L-carnitine, and obtained their associations with coronary artery disease (CAD), ischemic stroke, heart failure, and atrial fibrillation, as well as CVD risk factors (type 2 diabetes, glucose, HbA1c, insulin, lipid profile, blood pressure and body mass index) in large consortia and established cohorts, as well as sex-specific association in the UK Biobank." | 4.12 | L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study. ( Burgess, S; Fan, B; Schooling, CM; Zhao, JV, 2022) |
| "Our results demonstrated that the biomarker panels consisted of specific amino acids and acylcarnitines which could reflect the metabolic variations among the different stages of diabetes and might be useful for the differential diagnosis of prediabetes, overt diabetes and diabetic complications." | 4.02 | Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications. ( Hu, R; Li, X; Li, Y; Liang, Y; Liu, Y; Xu, W, 2021) |
| "Carnitine orotate complex (Godex) has been shown to decrease glycated hemoglobin levels and improve steatosis in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease." | 4.02 | Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway. ( Hong, JH; Lee, MK, 2021) |
| "Circulating acyl-carnitines (acyl-CNTs) are associated with insulin resistance (IR) and type 2 diabetes (T2D) in both rodents and humans." | 3.85 | Palmitoyl-carnitine production by blood cells associates with the concentration of circulating acyl-carnitines in healthy overweight women. ( Abate, N; Asghar, R; Brasier, AR; Camacho-Hughes, M; Chondronikola, M; Dillon, EL; Durham, WJ; Porter, C; Sheffield-Moore, M; Sidossis, L; Tuvdendorj, D; Volpi, E; Wu, Z; Zhang, X; Zhao, Y, 2017) |
| "What is the central question of this study? Does improved metabolic health and insulin sensitivity following a weight-loss and fitness intervention in sedentary, obese women alter exercise-associated fuel metabolism and incomplete mitochondrial fatty acid oxidation (FAO), as tracked by blood acylcarnitine patterns? What is the main finding and its importance? Despite improved fitness and blood sugar control, indices of incomplete mitochondrial FAO increased in a similar manner in response to a fixed load acute exercise bout; this indicates that intramitochondrial muscle FAO is inherently inefficient and is tethered directly to ATP turnover." | 3.85 | Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons. ( Adams, SH; Burnett, DJ; Campbell, C; Casazza, GA; Chandler, CJ; Fernandez, JR; Fiehn, O; Garvey, WT; Harper, ME; Hoppel, CL; Hughen, RW; Hunter, GR; Keim, NL; Light, AR; Newman, JW; Souza, EC; Zhang, J, 2017) |
| " Clinical improvements in insulin sensitivity, energy metabolism, and inflammation were related to metabolic alterations of free fatty acids (FFAs), acylcarnitines, amino acids, bile acids, and lipids species." | 3.83 | Metabolomics Study of Roux-en-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry. ( Bao, Y; Gao, P; Hong, CS; Jia, W; Luo, P; Tu, Y; Wei, L; Xu, G; Yin, P; Yu, H; Zhang, P; Zhao, X; Zhuang, Z, 2016) |
| "In type 1 diabetes (T1D), type 2 diabetes (T2D) and metabolic syndrome (MetS), the associated complex metabolomic changes in the involvement of carnitine metabolism in total carnitine ester level has already been documented; here we extended the investigations to the individual acylcarnitines." | 3.79 | Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome. ( Bagosi, Z; Bene, J; Bujtor, Z; Gasztonyi, B; Márton, M; Melegh, B; Mohás, M; Oroszlán, T; Wittmann, I, 2013) |
| " Serum markers of endothelial dysfunction and inflammation were unchanged, but short-chain acylcarnitine concentrations were significantly decreased." | 3.79 | Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease. ( Baldwin, A; Blewett, H; Guzman, RP; O, K; Taylor, CG; Weighell, W; Wright, B; Zahradka, P, 2013) |
| "Alterations in serum concentrations of several acylcarnitines, in particular tetradecenoylcarnitine (C14:1), tetradecadienylcarnitine (C14:2), octadecenoylcarnitine (C18:1) and malonylcarnitine/hydroxybutyrylcarnitine (C3DC+C4OH) are associated not only with T2D but also with prediabetic states." | 3.79 | Serum levels of acylcarnitines are altered in prediabetic conditions. ( Fiedler, GM; Kovacs, P; Leichtle, AB; Mai, M; Stumvoll, M; Tönjes, A, 2013) |
| "To elucidate the relationship between carnitine metabolism and plasma ketone body concentrations in moderately obese patients with mild glucose intolerance, the ketone body and carnitine levels in the basal state were determined in 72 obese patients: 20 with normal glucose tolerance (NGT), 29 with impaired glucose tolerance (IGT), and 23 with non-insulin-dependent diabetes mellitus (NIDDM) having a fasting plasma glucose (FPG) level of less than 200 mg/dl." | 3.69 | Changes in carnitine metabolism with ketone body production in obese glucose-intolerant patients. ( Imamura, K; Inokuchi, T; Isogai, S; Nomoto, K; Nomura, K, 1995) |
| "Spillover of AC occurs in type 2 diabetes but is not fully established in FH+." | 2.87 | Plasma Palmitoyl-Carnitine (AC16:0) Is a Marker of Increased Postprandial Nonesterified Incomplete Fatty Acid Oxidation Rate in Adults With Type 2 Diabetes. ( Bouchouirab, FZ; Carpentier, AC; Dubé, J; Fortin, M; Noll, C, 2018) |
| "Treatment with carnitine-orotate complex improves serum ALT and may improve hepatic steatosis as assessed by CT in patients with diabetes and NAFLD." | 2.80 | Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial. ( Bae, JC; Cho, YY; Han, KA; Ju, YC; Lee, KW; Lee, MK; Lee, WJ; Lee, WY; Park, JY; Son, HS; Woo, JT; Yoon, KH, 2015) |
| "The carnitine group was administered levo-carnitine 200 mg/kg/day intraperitoneally for 6 days." | 2.78 | Levo-carnitine reduces oxidative stress and improves contractile functions of fast muscles in type 2 diabetic rats. ( Bin Aleem, S; Farooq, Y; Hussain, MM, 2013) |
| "Patients with type 2 diabetes are under high oxidative stress, and levels of hyperglycemia correlate strongly with levels of LDL oxidation." | 2.74 | L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes. ( Avitabile, T; Cammalleri, L; Malaguarnera, M; Motta, M; Vacante, M, 2009) |
| " Patients were randomized in three groups, each of them composed by 14 patients (7 DB and 7 NDB): the first group was submitted to infusional PLC therapy at a dosage of 4 fl (total: 1,200 mg PLC) in 250 cc of physiological solution for 5 days a week for 4 weeks; the second group was treated with PLC in association with pulsed muscular compression therapy by Vascupump (5 sessions a week for 4 weeks); the third group was submitted only to Vascupump." | 2.73 | Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II. ( Izzo, A; Koverech, A; Liguori, M; Messano, M; Palermo, G; Riccioni, C; Sarcinella, R; Virmani, A, 2008) |
| " Simvastatin was administered, in both groups, at a dosage of 20 mg/day, while l-carnitine was administered at a dosage of 2g/day once daily." | 2.72 | Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus. ( Capurso, A; Capurso, C; Capurso, SA; Colacicco, AM; D'Introno, A; Fontana, C; Gadaleta, AM; Koverech, A; Panza, F; Solfrizzi, V; Torres, F, 2006) |
| "Seventy-four patients with NIDDM-associated PAD were treated with PLC (2 g/day) or placebo for 12 months." | 2.72 | Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD. ( Gabriella, C; Gea, OC; Giuseppe, M; Giuseppe, P; Luigi, DP; Margherita, F; Massimiliano, A; Roberto, F; Santo, SS; Sergio, N, 2006) |
| " In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1." | 2.71 | Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. ( Acerra, G; del Guercio, R; Fasano, C; Federico, P; Gioia, F; Madrid, E; Mattera, E; Ragozzino, G; Salomone, P, 2004) |
| "Significant improvement of hemodynamics following propionyl-L-carnitine administration in diabetic patients undergoing on-bypass coronary surgery was accompanied by reduced trans-cardiac endothelin difference and rapid hypoxanthine washout during reperfusion suggesting improvement of metabolism or vascular function." | 2.71 | Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients. ( Lango, R; Lysiak-Szydłowska, W; Rogowski, J; Siebert, J; Smoleński, RT; Słomińska, EM; Wujtewicz, M; Yacoub, MH, 2005) |
| "A total of 1,035 patients with NIDDM and IDDM were included." | 2.69 | Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. ( Abbott, CA; Boulton, AJ; Carrington, AL; Vileikyte, L; Williamson, S, 1998) |
| "Carnitine levels were observed before and during metabolic intervention with dietary measures and either sulfonylurea or insulin treatment." | 2.67 | No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients. ( Kaiser, E; Pregant, P; Schernthaner, G, 1993) |
| "L-carnitine was given orally, 2 g twice daily, for 45 weeks." | 2.66 | [The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II]. ( Cantini, F; Digiesi, V; Palchetti, R, 1989) |
| "Type 2 diabetes is a highly prevalent chronic metabolic disorder characterized by hyperglycemia and associated with several complications such as retinopathy, hyperlipidemia and polyneuropathy." | 2.58 | Role of carnitine and its derivatives in the development and management of type 2 diabetes. ( Bene, J; Hadzsiev, K; Melegh, B, 2018) |
| "Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease." | 2.47 | Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. ( Alvarez de Sotomayor, M; Herrera, MD; Justo, ML; Mingorance, C; Rodríguez-Rodríguez, R, 2011) |
| "2 mg/kg/min, without a significant dose-response effect." | 2.42 | Carnitine in type 2 diabetes. ( Mingrone, G, 2004) |
| "Diabetic retinopathy is a common complication of type 2 diabetes mellitus (T2DM)." | 1.72 | Relationship Between Acylcarnitine and the Risk of Retinopathy in Type 2 Diabetes Mellitus. ( Fang, ZZ; Gao, XQ; Li, X; Liu, X; Wang, WY, 2022) |
| "In patients with type 2 diabetes mellitus (T2DM), it is unknown whether acylcarnitine changes in the patient's plasma as diabetic peripheral neuropathy (DPN) occurs." | 1.72 | Correlation between Acylcarnitine and Peripheral Neuropathy in Type 2 Diabetes Mellitus. ( An, Z; Jiang, D; Liu, C; Wei, D; Xing, X; Zheng, D, 2022) |
| "The number of people affected by Type 2 diabetes mellitus (T2DM) is close to half a billion and is on a sharp rise, representing a major and growing public health burden." | 1.62 | Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes. ( Bararpour, N; Darrous, L; Froguel, P; Gasser, M; Gilardi, F; Kutalik, Z; Marques-Vidal, P; Porcu, E; Thomas, A; Waeber, G; Yengo, L, 2021) |
| "In participants with type 2 diabetes, after Bonferroni correction and rigorous adjustment, SDNN was inversely associated with higher levels of diacyl-phosphatidylcholine (PCaa) C32:0, PCaa C34:1, acyl-alkyl-phosphatidylcholine (PCae) C36:0, SM C16:0 and SM C16:1." | 1.62 | Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes. ( Bönhof, GJ; Knebel, B; Kotzka, J; Roden, M; Straßburger, K; Strom, A; Szendroedi, J; Ziegler, D, 2021) |
| "Acylcarnitine is an intermediate product of fatty acid oxidation." | 1.62 | Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study. ( An, ZN; Ge, MH; Jiang, DW; Liu, C; Shen, XL; Wei, DZ; Xing, XJ; Zheng, DM, 2021) |
| "Tuberculosis (TB) and type 2 diabetes mellitus (DM), a major TB risk factor, are both accompanied by marked alterations in metabolic processes." | 1.51 | Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatment. ( Alisjahbana, B; Hankemeier, T; Harms, AC; Joosten, SA; Ottenhoff, THM; Sahiratmadja, E; van Crevel, R; Vrieling, F, 2019) |
| "Carnitine was a major contributor to the pathway differences." | 1.51 | Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy. ( Brantley, MA; Burgess, LG; Cherney, EF; Chocron, IM; Ferreira, AJ; Goodale, MP; Herren, DJ; Jones, DP; Law, JC; Ma, C; Mitchell, SL; Osborn, MP; Sumarriva, K; Uppal, K; Wang, Y; Warden, C, 2019) |
| "Insulin resistance (IR) predisposes to type 2 diabetes and cardiovascular disease but its causes are incompletely understood." | 1.48 | Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance. ( Ärnlöv, J; Berne, C; Broeckling, CD; Castillejo-Lopez, C; Cook, NL; Fall, T; Ganna, A; Giedraitis, V; Hetty, S; Ingelsson, E; Lind, L; Nowak, C; Prenni, JE; Salihovic, S; Shen, X; Sundström, J, 2018) |
| "Acylcarnitines were suggested as early biomarkers even prior to insulin resistance in animal studies, but their roles in predicting type 2 diabetes were unknown." | 1.43 | Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study. ( Gao, X; Hu, FB; Hu, Y; Jin, Q; Li, H; Li, R; Liang, L; Lin, X; Liu, Y; Ma, Y; Sun, L; Wang, F; Wu, J; Yao, P; Zeng, R; Zhang, H, 2016) |
| "Offspring of type 2 diabetes (T2D) patients have increased risk to develop diabetes, due to inherited genetic susceptibility that directly interferes with the individual adaption to environmental conditions." | 1.43 | Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT). ( Barsch, A; Fuchser, J; Haas, J; Knebel, B; Kotzka, J; Lange, S; Lehr, S; Mack, S; Müller-Wieland, D; Schiller, M; Zurek, G, 2016) |
| "Pioglitazone treatment restored in vivo muscle oxidative capacity in diabetic rats to the level of lean controls." | 1.42 | Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes. ( Ciapaite, J; Houten, SM; Nicolay, K; Prompers, JJ; van den Broek, NM; Wessels, B, 2015) |
| "Although evidence that type 2 diabetes mellitus (T2DM) is accompanied by mitochondrial dysfunction in skeletal muscle has been accumulating, a causal link between mitochondrial dysfunction and the pathogenesis of the disease remains unclear." | 1.40 | Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat. ( Affolter, A; Clanachan, AS; Hersberger, M; Lemieux, H; Lou, PH; Lucchinetti, E; Warren, BE; Zaugg, M; Zhang, L, 2014) |
| "Dietary patterns related to type 2 diabetes-relevant metabolites included high intake of red meat and low intake of whole-grain bread, tea, coffee, cake and cookies, canned fruits and fish." | 1.39 | Variation of serum metabolites related to habitual diet: a targeted metabolomic approach in EPIC-Potsdam. ( Adamski, J; Boeing, H; Drogan, D; Floegel, A; Pischon, T; Prehn, C; Schulze, MB; von Ruesten, A, 2013) |
| "Amino acid concentrations were lower in type 2 diabetes compared with NW." | 1.38 | Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation. ( Arslanian, SA; Bacha, F; Chace, DH; de las Heras, J; DeJesus, VR; Lee, S; Michaliszyn, SF; Mihalik, SJ; Vockley, J, 2012) |
| "Insulin sensitivity was different (p < 0." | 1.37 | Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes. ( Andersen, JL; Dela, F; Hansen, CN; Helge, JW; Hey-Mogensen, M; Larsen, S; Madsbad, S; Stride, N; Worm, D, 2011) |
| "L-carnitine levels were lower in patients with type 2 DM (52." | 1.37 | [Low L-carnitine levels: can it be a cause of nocturnal blood pressure changes in patients with type 2 diabetes mellitus?]. ( Aydın, H; Candan, F; Içağasıoğlu, S; Kılıçlı, F; Korkmaz, S; Yıldız, G; Yılmaz, A, 2011) |
| "Carnitine levels were lower in type 2 diabetes group than control group (52." | 1.36 | Inspiratory muscle strength is correlated with carnitine levels in type 2 diabetes. ( Acibucu, F; Amasyali, E; Cakir, I; Candan, F; Dal, K; Dökmetaş, S; Fakioğlu, K; Kiliçli, F; Korkmaz, S; Ozşahin, S, 2010) |
| "As L-carnitine plays a pivotal role in the balanced metabolism of fatty acids and carbohydrates, this study was carried out to investigate whether long-term mildronate treatment could influence glucose levels and prevent diabetic complications in an experimental model of type 2 diabetes in Goto-Kakizaki (GK) rats." | 1.35 | Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats. ( Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Skapare, E; Svalbe, B; Vilskersts, R; Zvejniece, L, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.73) | 18.7374 |
| 1990's | 11 (8.03) | 18.2507 |
| 2000's | 22 (16.06) | 29.6817 |
| 2010's | 71 (51.82) | 24.3611 |
| 2020's | 32 (23.36) | 2.80 |
| Authors | Studies |
|---|---|
| van Liempd, S | 1 |
| Cabrera, D | 1 |
| Pilzner, C | 1 |
| Kollmus, H | 1 |
| Schughart, K | 1 |
| Falcón-Pérez, JM | 1 |
| Zheng, DM | 1 |
| An, ZN | 1 |
| Ge, MH | 1 |
| Wei, DZ | 1 |
| Jiang, DW | 1 |
| Xing, XJ | 1 |
| Shen, XL | 1 |
| Liu, C | 2 |
| Ruiz-Canela, M | 3 |
| Guasch-Ferré, M | 3 |
| Razquin, C | 2 |
| Toledo, E | 3 |
| Hernández-Alonso, P | 2 |
| Clish, CB | 2 |
| Li, J | 6 |
| Wittenbecher, C | 2 |
| Dennis, C | 3 |
| Alonso-Gómez, Á | 1 |
| Almanza-Aguilera, E | 1 |
| Liang, L | 4 |
| Corella, D | 3 |
| Gómez-Gracia, E | 1 |
| Estruch, R | 3 |
| Fiol, M | 2 |
| Lapetra, J | 2 |
| Serra-Majem, L | 2 |
| Ros, E | 3 |
| Arós, F | 2 |
| Salas-Salvadó, J | 3 |
| Hu, FB | 4 |
| Martínez-González, MÁ | 3 |
| An, Z | 1 |
| Zheng, D | 2 |
| Wei, D | 1 |
| Jiang, D | 1 |
| Xing, X | 1 |
| Wang, WY | 1 |
| Liu, X | 2 |
| Gao, XQ | 1 |
| Li, X | 3 |
| Fang, ZZ | 2 |
| Wargny, M | 1 |
| Croyal, M | 1 |
| Ragot, S | 1 |
| Gand, E | 1 |
| Jacobi, D | 1 |
| Trochu, JN | 1 |
| Prieur, X | 1 |
| Le May, C | 1 |
| Goronflot, T | 1 |
| Cariou, B | 1 |
| Saulnier, PJ | 1 |
| Hadjadj, S | 1 |
| Wedekind, R | 1 |
| Rothwell, JA | 1 |
| Viallon, V | 1 |
| Keski-Rahkonen, P | 1 |
| Schmidt, JA | 1 |
| Chajes, V | 1 |
| Katzke, V | 1 |
| Johnson, T | 1 |
| Santucci de Magistris, M | 1 |
| Krogh, V | 1 |
| Amiano, P | 1 |
| Sacerdote, C | 1 |
| Redondo-Sánchez, D | 1 |
| Huerta, JM | 1 |
| Tjønneland, A | 1 |
| Pokharel, P | 1 |
| Jakszyn, P | 1 |
| Tumino, R | 1 |
| Ardanaz, E | 1 |
| Sandanger, TM | 1 |
| Winkvist, A | 1 |
| Hultdin, J | 1 |
| Schulze, MB | 2 |
| Weiderpass, E | 1 |
| Gunter, MJ | 1 |
| Huybrechts, I | 1 |
| Scalbert, A | 1 |
| Mattman, A | 1 |
| Masoudi, R | 1 |
| Stockler-Ipsiroglu, S | 1 |
| Zivkovic, I | 1 |
| Lehman, A | 1 |
| Dionne, JM | 1 |
| Zhao, JV | 1 |
| Burgess, S | 1 |
| Fan, B | 1 |
| Schooling, CM | 1 |
| Wang, Z | 2 |
| Tang, J | 1 |
| Jin, E | 1 |
| Ren, C | 1 |
| Li, S | 3 |
| Zhang, L | 3 |
| Zhong, Y | 1 |
| Cao, Y | 1 |
| Wang, J | 2 |
| Zhou, W | 1 |
| Zhao, M | 2 |
| Huang, L | 2 |
| Qu, J | 1 |
| Sánchez-Quintero, MJ | 1 |
| Delgado, J | 1 |
| Medina-Vera, D | 1 |
| Becerra-Muñoz, VM | 1 |
| Queipo-Ortuño, MI | 1 |
| Estévez, M | 1 |
| Plaza-Andrades, I | 1 |
| Rodríguez-Capitán, J | 1 |
| Sánchez, PL | 1 |
| Crespo-Leiro, MG | 1 |
| Jiménez-Navarro, MF | 1 |
| Pavón-Morón, FJ | 1 |
| Qutob, HMH | 1 |
| Saad, RA | 1 |
| Bali, H | 1 |
| Osailan, A | 1 |
| Jaber, J | 1 |
| Alzahrani, E | 1 |
| Alyami, J | 1 |
| Elsayed, H | 1 |
| Alserihi, R | 1 |
| Shaikhomar, OA | 1 |
| Divya, KM | 1 |
| Savitha, DP | 1 |
| Krishna, GA | 1 |
| Dhanya, TM | 1 |
| Mohanan, PV | 1 |
| Shah, SF | 1 |
| Jafry, AT | 1 |
| Hussain, G | 1 |
| Kazim, AH | 1 |
| Ali, M | 1 |
| Rivani, E | 1 |
| Endraswari, PD | 1 |
| Widodo, ADW | 1 |
| Khalil, MR | 1 |
| Guldberg, R | 1 |
| Nørgård, BM | 1 |
| Uldbjerg, N | 1 |
| Wehberg, S | 1 |
| Fowobaje, KR | 1 |
| Mashood, LO | 1 |
| Ekholuenetale, M | 1 |
| Ibidoja, OJ | 1 |
| Romagnoli, A | 1 |
| D'Agostino, M | 1 |
| Pavoni, E | 1 |
| Ardiccioni, C | 1 |
| Motta, S | 1 |
| Crippa, P | 1 |
| Biagetti, G | 1 |
| Notarstefano, V | 1 |
| Rexha, J | 1 |
| Perta, N | 1 |
| Barocci, S | 1 |
| Costabile, BK | 1 |
| Colasurdo, G | 1 |
| Caucci, S | 1 |
| Mencarelli, D | 1 |
| Turchetti, C | 1 |
| Farina, M | 1 |
| Pierantoni, L | 1 |
| La Teana, A | 1 |
| Al Hadi, R | 1 |
| Cicconardi, F | 1 |
| Chinappi, M | 1 |
| Trucchi, E | 1 |
| Mancia, F | 1 |
| Menzo, S | 1 |
| Morozzo Della Rocca, B | 1 |
| D'Annessa, I | 1 |
| Di Marino, D | 1 |
| Choya, A | 1 |
| de Rivas, B | 1 |
| Gutiérrez-Ortiz, JI | 1 |
| López-Fonseca, R | 1 |
| Xu, S | 1 |
| Cheng, B | 1 |
| Huang, Z | 1 |
| Liu, T | 1 |
| Li, Y | 4 |
| Jiang, L | 1 |
| Guo, W | 1 |
| Xiong, J | 1 |
| Amirazodi, M | 1 |
| Daryanoosh, F | 1 |
| Mehrabi, A | 1 |
| Gaeini, A | 1 |
| Koushkie Jahromi, M | 1 |
| Salesi, M | 1 |
| Zarifkar, AH | 1 |
| Studeny, P | 1 |
| Netukova, M | 1 |
| Nemcokova, M | 1 |
| Klimesova, YM | 1 |
| Krizova, D | 1 |
| Kang, H | 1 |
| Tao, Y | 1 |
| Zhang, Q | 1 |
| Sha, D | 1 |
| Chen, Y | 2 |
| Yao, J | 1 |
| Gao, Y | 1 |
| Liu, J | 1 |
| Ji, L | 2 |
| Shi, P | 1 |
| Shi, C | 1 |
| Wu, YL | 1 |
| Wright, AI | 1 |
| M El-Metwaly, N | 1 |
| A Katouah, H | 1 |
| El-Desouky, MG | 1 |
| El-Bindary, AA | 1 |
| El-Bindary, MA | 1 |
| Kostakis, ID | 1 |
| Raptis, DA | 1 |
| Davidson, BR | 1 |
| Iype, S | 1 |
| Nasralla, D | 1 |
| Imber, C | 1 |
| Sharma, D | 1 |
| Pissanou, T | 1 |
| Pollok, JM | 1 |
| Hughes, AM | 1 |
| Sanderson, E | 1 |
| Morris, T | 1 |
| Ayorech, Z | 1 |
| Tesli, M | 1 |
| Ask, H | 1 |
| Reichborn-Kjennerud, T | 1 |
| Andreassen, OA | 1 |
| Magnus, P | 1 |
| Helgeland, Ø | 1 |
| Johansson, S | 1 |
| Njølstad, P | 1 |
| Davey Smith, G | 1 |
| Havdahl, A | 1 |
| Howe, LD | 1 |
| Davies, NM | 1 |
| Amrillah, T | 1 |
| Prasetio, A | 1 |
| Supandi, AR | 1 |
| Sidiq, DH | 1 |
| Putra, FS | 1 |
| Nugroho, MA | 1 |
| Salsabilla, Z | 1 |
| Azmi, R | 1 |
| Grammatikopoulos, P | 1 |
| Bouloumis, T | 1 |
| Steinhauer, S | 1 |
| Mironov, VS | 2 |
| Bazhenova, TA | 2 |
| Manakin, YV | 2 |
| Yagubskii, EB | 2 |
| Yakushev, IA | 1 |
| Gilmutdinov, IF | 1 |
| Simonov, SV | 1 |
| Lan, K | 1 |
| Yang, H | 1 |
| Zheng, J | 1 |
| Hu, H | 1 |
| Zhu, T | 1 |
| Zou, X | 1 |
| Hu, B | 1 |
| Liu, H | 1 |
| Olokede, O | 1 |
| Wu, H | 1 |
| Holtzapple, M | 1 |
| Gungor, O | 1 |
| Kose, M | 1 |
| Ghaemi, R | 1 |
| Acker, M | 1 |
| Stosic, A | 1 |
| Jacobs, R | 1 |
| Selvaganapathy, PR | 1 |
| Ludwig, N | 1 |
| Yerneni, SS | 1 |
| Azambuja, JH | 1 |
| Pietrowska, M | 1 |
| Widłak, P | 1 |
| Hinck, CS | 1 |
| Głuszko, A | 1 |
| Szczepański, MJ | 1 |
| Kärmer, T | 1 |
| Kallinger, I | 1 |
| Schulz, D | 1 |
| Bauer, RJ | 1 |
| Spanier, G | 1 |
| Spoerl, S | 1 |
| Meier, JK | 1 |
| Ettl, T | 1 |
| Razzo, BM | 1 |
| Reichert, TE | 1 |
| Hinck, AP | 1 |
| Whiteside, TL | 1 |
| Wei, ZL | 1 |
| Juan, W | 1 |
| Tong, D | 1 |
| Juan, LX | 1 |
| Sa, LY | 1 |
| Jie, HFM | 1 |
| Xiao, G | 1 |
| Xiang, LG | 1 |
| Jie, HM | 1 |
| Xu, C | 1 |
| Yu, DN | 1 |
| Yao, ZX | 1 |
| Bigdeli, F | 1 |
| Gao, XM | 1 |
| Cheng, X | 1 |
| Li, JZ | 1 |
| Zhang, JW | 1 |
| Wang, W | 2 |
| Guan, ZJ | 1 |
| Bu, Y | 1 |
| Liu, KG | 1 |
| Morsali, A | 1 |
| Das, R | 1 |
| Paul, R | 1 |
| Parui, A | 1 |
| Shrotri, A | 1 |
| Atzori, C | 1 |
| Lomachenko, KA | 1 |
| Singh, AK | 1 |
| Mondal, J | 1 |
| Peter, SC | 1 |
| Florimbio, AR | 1 |
| Coughlin, LN | 1 |
| Bauermeister, JA | 1 |
| Young, SD | 1 |
| Zimmerman, MA | 1 |
| Walton, MA | 1 |
| Bonar, EE | 1 |
| Demir, D | 1 |
| Balci, AB | 1 |
| Kahraman, N | 1 |
| Sunbul, SA | 1 |
| Gucu, A | 1 |
| Seker, IB | 1 |
| Badem, S | 1 |
| Yuksel, A | 1 |
| Ozyazicioglu, AF | 1 |
| Goncu, MT | 1 |
| Zhang, H | 2 |
| Zhou, H | 1 |
| Deng, Z | 1 |
| Luo, L | 1 |
| Ong, SP | 1 |
| Wang, C | 2 |
| Xin, H | 1 |
| Whittingham, MS | 1 |
| Zhou, G | 1 |
| Maemura, R | 1 |
| Wakamatsu, M | 1 |
| Matsumoto, K | 1 |
| Sakaguchi, H | 1 |
| Yoshida, N | 1 |
| Hama, A | 1 |
| Yoshida, T | 1 |
| Miwata, S | 1 |
| Kitazawa, H | 1 |
| Narita, K | 1 |
| Kataoka, S | 1 |
| Ichikawa, D | 1 |
| Hamada, M | 1 |
| Taniguchi, R | 1 |
| Suzuki, K | 1 |
| Kawashima, N | 1 |
| Nishikawa, E | 1 |
| Narita, A | 1 |
| Okuno, Y | 1 |
| Nishio, N | 1 |
| Kato, K | 1 |
| Kojima, S | 1 |
| Morita, K | 1 |
| Muramatsu, H | 1 |
| Takahashi, Y | 1 |
| Yirgu, A | 1 |
| Mekonnen, Y | 1 |
| Eyado, A | 1 |
| Staropoli, A | 1 |
| Vinale, F | 1 |
| Zac, J | 1 |
| Zac, S | 1 |
| Pérez-Padilla, R | 1 |
| Remigio-Luna, A | 1 |
| Guzmán-Boulloud, N | 1 |
| Gochicoa-Rangel, L | 1 |
| Guzmán-Valderrábano, C | 1 |
| Thirión-Romero, I | 1 |
| Statsenko, ME | 1 |
| Turkina, SV | 1 |
| Barantsevich, ER | 1 |
| Karakulova, YV | 1 |
| Baranova, NS | 1 |
| Morzhukhina, MV | 1 |
| Wang, Q | 1 |
| Gu, Y | 1 |
| Chen, C | 1 |
| Qiao, L | 1 |
| Pan, F | 1 |
| Song, C | 1 |
| Canetto, SS | 1 |
| Entilli, L | 1 |
| Cerbo, I | 1 |
| Cipolletta, S | 1 |
| Wu, Y | 2 |
| Zhu, P | 1 |
| Jiang, Y | 1 |
| Zhang, X | 3 |
| Xie, B | 1 |
| Song, T | 1 |
| Zhang, F | 1 |
| Luo, A | 1 |
| Xiong, X | 1 |
| Han, J | 1 |
| Peng, X | 1 |
| Li, M | 1 |
| Chen, Q | 1 |
| Fang, W | 1 |
| Hou, Y | 1 |
| Zhu, Y | 1 |
| Ye, J | 1 |
| Liu, L | 1 |
| Islam, MR | 1 |
| Sanderson, P | 1 |
| Johansen, MP | 1 |
| Payne, TE | 1 |
| Naidu, R | 1 |
| Cao, J | 1 |
| Yang, J | 1 |
| Niu, X | 1 |
| Zhai, Y | 1 |
| Qiang, C | 1 |
| Niu, Y | 1 |
| Li, Z | 1 |
| Dong, N | 1 |
| Wen, B | 1 |
| Ouyang, Z | 1 |
| Zhang, Y | 1 |
| Zhao, J | 1 |
| Morici, P | 1 |
| Rizzato, C | 1 |
| Ghelardi, E | 1 |
| Rossolini, GM | 1 |
| Lupetti, A | 1 |
| Gözüküçük, R | 1 |
| Cakiroglu, B | 1 |
| He, X | 1 |
| Li, R | 2 |
| Zhao, D | 1 |
| Ji, X | 1 |
| Fan, X | 1 |
| Chen, J | 1 |
| Wang, Y | 2 |
| Luo, Y | 1 |
| Xie, L | 1 |
| Sun, S | 1 |
| Cai, Z | 1 |
| Liu, Q | 1 |
| Ma, K | 1 |
| Sun, X | 1 |
| Drinkwater, JJ | 1 |
| Davis, TME | 1 |
| Turner, AW | 1 |
| Davis, WA | 1 |
| Suzuki, Y | 1 |
| Mizuta, Y | 1 |
| Mikagi, A | 1 |
| Misawa-Suzuki, T | 1 |
| Tsuchido, Y | 1 |
| Sugaya, T | 1 |
| Hashimoto, T | 1 |
| Ema, K | 1 |
| Hayashita, T | 1 |
| Qi, L | 3 |
| Ye, Z | 1 |
| Lin, H | 1 |
| Taghizadeh, H | 1 |
| Emamgholipour, S | 1 |
| Hosseinkhani, S | 1 |
| Arjmand, B | 1 |
| Rezaei, N | 1 |
| Dilmaghani-Marand, A | 1 |
| Ghasemi, E | 1 |
| Panahi, N | 1 |
| Dehghanbanadaki, H | 1 |
| Ghodssi-Ghassemabadi, R | 1 |
| Najjar, N | 1 |
| Asadi, M | 1 |
| Khoshniat, M | 1 |
| Larijani, B | 1 |
| Razi, F | 1 |
| Dong, K | 1 |
| Li, C | 1 |
| Wang, G | 1 |
| Lin, X | 2 |
| Zhao, H | 1 |
| Nie, Q | 1 |
| Xing, M | 1 |
| Chen, H | 1 |
| Hu, J | 1 |
| Nie, S | 1 |
| Ottosson, F | 1 |
| Smith, E | 1 |
| Gallo, W | 1 |
| Fernandez, C | 1 |
| Melander, O | 1 |
| Vrieling, F | 1 |
| Alisjahbana, B | 1 |
| Sahiratmadja, E | 1 |
| van Crevel, R | 1 |
| Harms, AC | 1 |
| Hankemeier, T | 1 |
| Ottenhoff, THM | 1 |
| Joosten, SA | 1 |
| Zhang, K | 1 |
| Han, Y | 1 |
| Zhao, Q | 1 |
| Zhan, T | 1 |
| Sun, W | 1 |
| Sun, D | 4 |
| Si, X | 1 |
| Yu, X | 1 |
| Qin, Y | 1 |
| Tang, C | 1 |
| Zhang, J | 2 |
| Muilwijk, M | 1 |
| Goorden, SMI | 1 |
| Celis-Morales, C | 1 |
| Hof, MH | 1 |
| Ghauharali-van der Vlugt, K | 1 |
| Beers-Stet, FS | 1 |
| Gill, JMR | 1 |
| Vaz, FM | 1 |
| van Valkengoed, IGM | 1 |
| Zhao, S | 1 |
| Feng, XF | 1 |
| Huang, T | 1 |
| Luo, HH | 1 |
| Chen, JX | 1 |
| Zeng, J | 1 |
| Gu, M | 1 |
| Sun, XY | 1 |
| Yang, X | 1 |
| Cao, YF | 1 |
| Herzog, K | 1 |
| Berggren, J | 1 |
| Al Majdoub, M | 1 |
| Balderas Arroyo, C | 1 |
| Lindqvist, A | 1 |
| Hedenbro, J | 1 |
| Groop, L | 1 |
| Wierup, N | 1 |
| Spégel, P | 2 |
| Pagano, G | 1 |
| Pallardó, FV | 1 |
| Lyakhovich, A | 1 |
| Tiano, L | 1 |
| Fittipaldi, MR | 1 |
| Toscanesi, M | 1 |
| Trifuoggi, M | 1 |
| Gunther, SH | 1 |
| Khoo, CM | 1 |
| Tai, ES | 1 |
| Sim, X | 1 |
| Kovalik, JP | 1 |
| Ching, J | 1 |
| Lee, JJ | 1 |
| van Dam, RM | 1 |
| Salihovic, S | 2 |
| Broeckling, CD | 2 |
| Ganna, A | 2 |
| Prenni, JE | 2 |
| Sundström, J | 2 |
| Berne, C | 2 |
| Lind, L | 2 |
| Ingelsson, E | 2 |
| Fall, T | 2 |
| Ärnlöv, J | 2 |
| Nowak, C | 2 |
| Ziegler, D | 1 |
| Strom, A | 1 |
| Straßburger, K | 1 |
| Knebel, B | 2 |
| Bönhof, GJ | 1 |
| Kotzka, J | 2 |
| Szendroedi, J | 1 |
| Roden, M | 1 |
| Didangelos, T | 1 |
| Karlafti, E | 1 |
| Kotzakioulafi, E | 1 |
| Kontoninas, Z | 1 |
| Margaritidis, C | 1 |
| Giannoulaki, P | 1 |
| Kantartzis, K | 1 |
| Drouin-Chartier, JP | 1 |
| Fitó, M | 2 |
| Babio, N | 1 |
| Bhupathiraju, SN | 1 |
| Jialal, I | 1 |
| Patel, A | 1 |
| Devaraj, S | 1 |
| Adams-Huet, B | 1 |
| Liang, Y | 1 |
| Hu, R | 1 |
| Xu, W | 1 |
| Liu, Y | 3 |
| Porcu, E | 1 |
| Gilardi, F | 1 |
| Darrous, L | 1 |
| Yengo, L | 1 |
| Bararpour, N | 1 |
| Gasser, M | 1 |
| Marques-Vidal, P | 1 |
| Froguel, P | 1 |
| Waeber, G | 1 |
| Thomas, A | 1 |
| Kutalik, Z | 1 |
| Wang, DD | 2 |
| Mao, YZ | 1 |
| He, SM | 1 |
| Yang, Y | 1 |
| Chen, X | 2 |
| Jahoor, F | 1 |
| Hsu, JW | 1 |
| Mehta, PB | 1 |
| Keene, KR | 1 |
| Gaba, R | 1 |
| Mulukutla, SN | 1 |
| Caducoy, E | 1 |
| Peacock, WF | 1 |
| Patel, SG | 1 |
| Bennet, R | 1 |
| Lernmark, A | 1 |
| Balasubramanyam, A | 1 |
| Hong, JH | 1 |
| Lee, MK | 2 |
| Fort, PE | 1 |
| Rajendiran, TM | 1 |
| Soni, T | 1 |
| Byun, J | 1 |
| Shan, Y | 1 |
| Looker, HC | 1 |
| Nelson, RG | 1 |
| Kretzler, M | 1 |
| Michailidis, G | 1 |
| Roger, JE | 1 |
| Gardner, TW | 1 |
| Abcouwer, SF | 1 |
| Pennathur, S | 1 |
| Afshinnia, F | 1 |
| Plomgaard, P | 1 |
| Weigert, C | 1 |
| Aichler, M | 1 |
| Borgmann, D | 1 |
| Krumsiek, J | 1 |
| Buck, A | 1 |
| MacDonald, PE | 1 |
| Fox, JEM | 1 |
| Lyon, J | 1 |
| Light, PE | 1 |
| Keipert, S | 1 |
| Jastroch, M | 1 |
| Feuchtinger, A | 1 |
| Mueller, NS | 1 |
| Sun, N | 1 |
| Palmer, A | 1 |
| Alexandrov, T | 1 |
| Hrabe de Angelis, M | 1 |
| Neschen, S | 1 |
| Tschöp, MH | 1 |
| Walch, A | 1 |
| Bouchouirab, FZ | 1 |
| Fortin, M | 1 |
| Noll, C | 1 |
| Dubé, J | 1 |
| Carpentier, AC | 1 |
| Heianza, Y | 2 |
| Smith, SR | 1 |
| Bray, GA | 2 |
| Sacks, FM | 2 |
| Strand, E | 2 |
| Rebnord, EW | 2 |
| Flygel, MR | 1 |
| Lysne, V | 1 |
| Svingen, GFT | 1 |
| Tell, GS | 1 |
| Løland, KH | 1 |
| Berge, RK | 2 |
| Svardal, A | 2 |
| Nygård, O | 1 |
| Pedersen, ER | 2 |
| Batchuluun, B | 1 |
| Al Rijjal, D | 1 |
| Prentice, KJ | 1 |
| Eversley, JA | 1 |
| Burdett, E | 1 |
| Mohan, H | 1 |
| Bhattacharjee, A | 1 |
| Gunderson, EP | 1 |
| Wheeler, MB | 1 |
| Romero-Ibarguengoitia, ME | 1 |
| Vadillo-Ortega, F | 1 |
| Caballero, AE | 1 |
| Ibarra-González, I | 1 |
| Herrera-Rosas, A | 1 |
| Serratos-Canales, MF | 1 |
| León-Hernández, M | 1 |
| González-Chávez, A | 1 |
| Mummidi, S | 1 |
| Duggirala, R | 1 |
| López-Alvarenga, JC | 1 |
| Imbe, A | 1 |
| Tanimoto, K | 1 |
| Inaba, Y | 1 |
| Sakai, S | 1 |
| Shishikura, K | 1 |
| Imbe, H | 1 |
| Tanimoto, Y | 1 |
| Terasaki, J | 1 |
| Imagawa, A | 1 |
| Hanafusa, T | 1 |
| Bene, J | 2 |
| Hadzsiev, K | 1 |
| Melegh, B | 2 |
| Safai, N | 1 |
| Suvitaival, T | 1 |
| Ali, A | 1 |
| Al-Majdoub, M | 1 |
| Carstensen, B | 1 |
| Vestergaard, H | 1 |
| Ridderstråle, M | 1 |
| Hetty, S | 1 |
| Castillejo-Lopez, C | 1 |
| Cook, NL | 1 |
| Shen, X | 1 |
| Giedraitis, V | 1 |
| Ramazani, M | 1 |
| Qujeq, D | 1 |
| Moazezi, Z | 1 |
| Liepinsh, E | 3 |
| Dambrova, M | 3 |
| Zheng, Y | 1 |
| Bulló, M | 1 |
| Clish, C | 1 |
| Papandreou, C | 1 |
| Samczuk, P | 1 |
| Hady, HR | 1 |
| Adamska-Patruno, E | 1 |
| Citko, A | 1 |
| Dadan, J | 1 |
| Barbas, C | 1 |
| Kretowski, A | 1 |
| Ciborowski, M | 1 |
| Diamanti, K | 1 |
| Cavalli, M | 1 |
| Pan, G | 1 |
| Pereira, MJ | 1 |
| Kumar, C | 1 |
| Skrtic, S | 1 |
| Grabherr, M | 1 |
| Risérus, U | 1 |
| Eriksson, JW | 1 |
| Komorowski, J | 1 |
| Wadelius, C | 1 |
| Sumarriva, K | 1 |
| Uppal, K | 1 |
| Ma, C | 1 |
| Herren, DJ | 1 |
| Chocron, IM | 1 |
| Warden, C | 1 |
| Mitchell, SL | 1 |
| Burgess, LG | 1 |
| Goodale, MP | 1 |
| Osborn, MP | 1 |
| Ferreira, AJ | 1 |
| Law, JC | 1 |
| Cherney, EF | 1 |
| Jones, DP | 1 |
| Brantley, MA | 1 |
| Zhou, T | 1 |
| DiDonato, JA | 1 |
| Pei, X | 1 |
| LeBoff, MS | 1 |
| Nicholas, DA | 1 |
| Proctor, EA | 1 |
| Agrawal, M | 1 |
| Belkina, AC | 1 |
| Van Nostrand, SC | 1 |
| Panneerseelan-Bharath, L | 1 |
| Jones, AR | 1 |
| Raval, F | 1 |
| Ip, BC | 1 |
| Zhu, M | 1 |
| Cacicedo, JM | 1 |
| Habib, C | 1 |
| Sainz-Rueda, N | 1 |
| Persky, L | 1 |
| Sullivan, PG | 1 |
| Corkey, BE | 1 |
| Apovian, CM | 1 |
| Kern, PA | 1 |
| Lauffenburger, DA | 1 |
| Nikolajczyk, BS | 1 |
| Vidal-Casariego, A | 1 |
| Burgos-Peláez, R | 1 |
| Martínez-Faedo, C | 1 |
| Calvo-Gracia, F | 1 |
| Valero-Zanuy, MÁ | 1 |
| Luengo-Pérez, LM | 1 |
| Cuerda-Compés, C | 1 |
| Floegel, A | 1 |
| von Ruesten, A | 1 |
| Drogan, D | 1 |
| Prehn, C | 2 |
| Adamski, J | 2 |
| Pischon, T | 1 |
| Boeing, H | 1 |
| Zahradka, P | 1 |
| Wright, B | 1 |
| Weighell, W | 1 |
| Blewett, H | 1 |
| Baldwin, A | 1 |
| O, K | 1 |
| Guzman, RP | 1 |
| Taylor, CG | 1 |
| Mai, M | 1 |
| Tönjes, A | 1 |
| Kovacs, P | 1 |
| Stumvoll, M | 1 |
| Fiedler, GM | 1 |
| Leichtle, AB | 1 |
| Warren, BE | 1 |
| Lou, PH | 1 |
| Lucchinetti, E | 1 |
| Clanachan, AS | 1 |
| Affolter, A | 1 |
| Hersberger, M | 1 |
| Zaugg, M | 1 |
| Lemieux, H | 1 |
| Rutkowsky, JM | 1 |
| Knotts, TA | 1 |
| Ono-Moore, KD | 1 |
| McCoin, CS | 1 |
| Huang, S | 1 |
| Schneider, D | 1 |
| Singh, S | 1 |
| Adams, SH | 3 |
| Hwang, DH | 2 |
| Zhang, C | 1 |
| Chen, L | 1 |
| Han, X | 1 |
| Anderson, SG | 1 |
| Dunn, WB | 1 |
| Banerjee, M | 1 |
| Brown, M | 1 |
| Broadhurst, DI | 1 |
| Goodacre, R | 1 |
| Cooper, GJ | 1 |
| Kell, DB | 1 |
| Cruickshank, JK | 1 |
| Wessels, B | 1 |
| Ciapaite, J | 1 |
| van den Broek, NM | 1 |
| Houten, SM | 2 |
| Nicolay, K | 1 |
| Prompers, JJ | 1 |
| Il'yasova, D | 1 |
| Wagenknecht, LE | 1 |
| Spasojevic, I | 1 |
| Watkins, S | 1 |
| Bowden, D | 1 |
| Wang, F | 2 |
| D'Agostino, RB | 1 |
| Bae, JC | 1 |
| Lee, WY | 1 |
| Yoon, KH | 1 |
| Park, JY | 1 |
| Son, HS | 1 |
| Han, KA | 1 |
| Lee, KW | 1 |
| Woo, JT | 1 |
| Ju, YC | 1 |
| Lee, WJ | 1 |
| Cho, YY | 1 |
| Virmani, A | 2 |
| Pinto, L | 1 |
| Bauermann, O | 1 |
| Zerelli, S | 1 |
| Diedenhofen, A | 1 |
| Binienda, ZK | 1 |
| Ali, SF | 1 |
| van der Leij, FR | 1 |
| Avalos-Soriano, A | 1 |
| De la Cruz-Cordero, R | 1 |
| López-Martínez, FJ | 1 |
| Rosado, JL | 1 |
| Duarte-Vázquez, MÁ | 1 |
| Garcia-Gasca, T | 1 |
| Mook-Kanamori, DO | 1 |
| de Mutsert, R | 1 |
| Rensen, PC | 1 |
| den Heijer, M | 1 |
| le Cessie, S | 1 |
| Suhre, K | 1 |
| Rosendaal, FR | 1 |
| van Dijk, KW | 1 |
| Salmanoglu, DS | 1 |
| Gurpinar, T | 1 |
| Vural, K | 1 |
| Ekerbicer, N | 1 |
| Darıverenli, E | 1 |
| Var, A | 1 |
| Hisano, Y | 1 |
| Kaneto, H | 1 |
| Kimura, T | 1 |
| Ota, T | 1 |
| Kamao, T | 1 |
| Uno, M | 1 |
| Mizushima, T | 1 |
| Mune, T | 1 |
| Kaku, K | 1 |
| Pallares-Méndez, R | 1 |
| Aguilar-Salinas, CA | 1 |
| Cruz-Bautista, I | 1 |
| Del Bosque-Plata, L | 1 |
| Luo, P | 1 |
| Yu, H | 1 |
| Zhao, X | 1 |
| Bao, Y | 1 |
| Hong, CS | 1 |
| Zhang, P | 1 |
| Tu, Y | 1 |
| Yin, P | 1 |
| Gao, P | 1 |
| Wei, L | 1 |
| Zhuang, Z | 1 |
| Jia, W | 1 |
| Xu, G | 1 |
| Trøseid, M | 1 |
| Hov, JR | 1 |
| Nestvold, TK | 1 |
| Thoresen, H | 1 |
| Lappegård, KT | 1 |
| Mack, S | 1 |
| Lehr, S | 1 |
| Barsch, A | 1 |
| Schiller, M | 1 |
| Haas, J | 1 |
| Lange, S | 1 |
| Fuchser, J | 1 |
| Zurek, G | 1 |
| Müller-Wieland, D | 1 |
| Sun, L | 1 |
| Gao, X | 1 |
| Yao, P | 1 |
| Hu, Y | 1 |
| Ma, Y | 1 |
| Jin, Q | 1 |
| Li, H | 1 |
| Zeng, R | 1 |
| Wu, J | 1 |
| Schooneman, MG | 1 |
| Napolitano, A | 1 |
| Ambler, GK | 1 |
| Murgatroyd, PR | 1 |
| Miller, SR | 1 |
| Hollak, CE | 1 |
| Tan, CY | 1 |
| Virtue, S | 1 |
| Vidal-Puig, A | 1 |
| Nunez, DJ | 1 |
| Soeters, MR | 1 |
| Hesselink, MK | 1 |
| Schrauwen-Hinderling, V | 1 |
| Schrauwen, P | 1 |
| Chondronikola, M | 1 |
| Asghar, R | 1 |
| Dillon, EL | 1 |
| Durham, WJ | 1 |
| Wu, Z | 1 |
| Porter, C | 1 |
| Camacho-Hughes, M | 1 |
| Zhao, Y | 1 |
| Brasier, AR | 1 |
| Volpi, E | 1 |
| Sheffield-Moore, M | 1 |
| Abate, N | 1 |
| Sidossis, L | 1 |
| Tuvdendorj, D | 1 |
| Ribel-Madsen, A | 1 |
| Ribel-Madsen, R | 1 |
| Brøns, C | 1 |
| Newgard, CB | 2 |
| Vaag, AA | 1 |
| Hellgren, LI | 1 |
| Light, AR | 1 |
| Hoppel, CL | 2 |
| Campbell, C | 1 |
| Chandler, CJ | 1 |
| Burnett, DJ | 1 |
| Souza, EC | 1 |
| Casazza, GA | 1 |
| Hughen, RW | 1 |
| Keim, NL | 1 |
| Newman, JW | 2 |
| Hunter, GR | 1 |
| Fernandez, JR | 1 |
| Garvey, WT | 2 |
| Harper, ME | 1 |
| Fiehn, O | 1 |
| González-Ortiz, M | 1 |
| Hernández-González, SO | 1 |
| Hernández-Salazar, E | 1 |
| Martínez-Abundis, E | 1 |
| Malaguarnera, M | 6 |
| Vacante, M | 3 |
| Avitabile, T | 2 |
| Cammalleri, L | 1 |
| Motta, M | 2 |
| Lok, KH | 1 |
| Zhao, L | 1 |
| Wong, SW | 1 |
| Minkler, PE | 1 |
| Vilskersts, R | 1 |
| Zvejniece, L | 1 |
| Svalbe, B | 1 |
| Skapare, E | 2 |
| Kuka, J | 1 |
| Cirule, H | 1 |
| Grinberga, S | 2 |
| Kalvinsh, I | 1 |
| Li Volti, G | 2 |
| Galvano, F | 2 |
| Antic, T | 1 |
| Mynatt, RL | 1 |
| Mihalik, SJ | 2 |
| Goodpaster, BH | 1 |
| Kelley, DE | 1 |
| Chace, DH | 2 |
| Vockley, J | 2 |
| Toledo, FG | 1 |
| DeLany, JP | 1 |
| Tassoni, E | 2 |
| Conti, R | 2 |
| Gallo, G | 1 |
| Vincenti, S | 1 |
| Dell'Uomo, N | 1 |
| Mastrofrancesco, L | 1 |
| Ricciolini, R | 1 |
| Cabri, W | 1 |
| Carminati, P | 2 |
| Giannessi, F | 2 |
| Kiliçli, F | 2 |
| Dökmetaş, S | 1 |
| Candan, F | 2 |
| Ozşahin, S | 1 |
| Korkmaz, S | 2 |
| Amasyali, E | 1 |
| Fakioğlu, K | 1 |
| Dal, K | 1 |
| Acibucu, F | 1 |
| Cakir, I | 1 |
| Derosa, G | 5 |
| Maffioli, P | 4 |
| Salvadeo, SA | 2 |
| Ferrari, I | 4 |
| Gravina, A | 2 |
| Mereu, R | 2 |
| D'Angelo, A | 4 |
| Palumbo, I | 4 |
| Randazzo, S | 4 |
| Cicero, AF | 5 |
| Fogari, E | 2 |
| Riccioni, C | 2 |
| Sarcinella, R | 2 |
| Izzo, A | 2 |
| Palermo, G | 2 |
| Liguori, M | 2 |
| Caliumi, C | 1 |
| Carloni, E | 1 |
| Paolucci, AM | 1 |
| D'andrea, P | 1 |
| Pompili, S | 1 |
| Yıldız, G | 1 |
| Yılmaz, A | 1 |
| Aydın, H | 1 |
| Içağasıoğlu, S | 1 |
| Mannucci, E | 1 |
| Pessotto, P | 1 |
| Arduini, A | 2 |
| Golbidi, S | 1 |
| Ebadi, SA | 1 |
| Laher, I | 1 |
| Larsen, S | 1 |
| Stride, N | 1 |
| Hey-Mogensen, M | 1 |
| Hansen, CN | 1 |
| Andersen, JL | 1 |
| Madsbad, S | 1 |
| Worm, D | 1 |
| Helge, JW | 1 |
| Dela, F | 1 |
| Mingorance, C | 1 |
| Rodríguez-Rodríguez, R | 1 |
| Justo, ML | 1 |
| Alvarez de Sotomayor, M | 1 |
| Herrera, MD | 1 |
| Ceccarelli, SM | 1 |
| Chomienne, O | 1 |
| Gubler, M | 1 |
| Laferrère, B | 1 |
| Reilly, D | 1 |
| Arias, S | 1 |
| Swerdlow, N | 1 |
| Gorroochurn, P | 1 |
| Bawa, B | 1 |
| Bose, M | 1 |
| Teixeira, J | 1 |
| Stevens, RD | 1 |
| Wenner, BR | 1 |
| Bain, JR | 1 |
| Muehlbauer, MJ | 1 |
| Haqq, A | 1 |
| Lien, L | 1 |
| Shah, SH | 1 |
| Svetkey, LP | 1 |
| Ringseis, R | 1 |
| Keller, J | 1 |
| Eder, K | 1 |
| Michaliszyn, SF | 1 |
| de las Heras, J | 1 |
| Bacha, F | 1 |
| Lee, S | 1 |
| DeJesus, VR | 1 |
| Arslanian, SA | 1 |
| Vavers, E | 1 |
| Konrade, I | 1 |
| Strele, I | 1 |
| Pugovics, O | 1 |
| Brockman, DA | 1 |
| Gallaher, DD | 1 |
| Bin Aleem, S | 2 |
| Hussain, MM | 2 |
| Farooq, Y | 2 |
| Márton, M | 1 |
| Mohás, M | 1 |
| Bagosi, Z | 1 |
| Bujtor, Z | 1 |
| Oroszlán, T | 1 |
| Gasztonyi, B | 1 |
| Wittmann, I | 1 |
| Gaddi, A | 1 |
| Mugellini, A | 1 |
| Ciccarelli, L | 1 |
| Fogari, R | 1 |
| Ragozzino, G | 1 |
| Mattera, E | 1 |
| Madrid, E | 1 |
| Salomone, P | 1 |
| Fasano, C | 1 |
| Gioia, F | 1 |
| Acerra, G | 1 |
| del Guercio, R | 1 |
| Federico, P | 1 |
| Mingrone, G | 2 |
| Rahbar, AR | 1 |
| Shakerhosseini, R | 1 |
| Saadat, N | 1 |
| Taleban, F | 1 |
| Pordal, A | 1 |
| Gollestan, B | 1 |
| Michno, A | 1 |
| Raszeja-Specht, A | 1 |
| Jankowska-Kulawy, A | 1 |
| Pawelczyk, T | 1 |
| Szutowicz, A | 1 |
| Lango, R | 1 |
| Smoleński, RT | 1 |
| Rogowski, J | 1 |
| Siebert, J | 1 |
| Wujtewicz, M | 1 |
| Słomińska, EM | 1 |
| Lysiak-Szydłowska, W | 1 |
| Yacoub, MH | 1 |
| Solfrizzi, V | 1 |
| Capurso, C | 1 |
| Colacicco, AM | 1 |
| D'Introno, A | 1 |
| Fontana, C | 1 |
| Capurso, SA | 1 |
| Torres, F | 1 |
| Gadaleta, AM | 1 |
| Koverech, A | 2 |
| Capurso, A | 1 |
| Panza, F | 1 |
| Santo, SS | 1 |
| Sergio, N | 1 |
| Luigi, DP | 1 |
| Giuseppe, M | 1 |
| Margherita, F | 1 |
| Gea, OC | 1 |
| Roberto, F | 1 |
| Gabriella, C | 1 |
| Giuseppe, P | 1 |
| Massimiliano, A | 1 |
| Poorabbas, A | 1 |
| Fallah, F | 1 |
| Bagdadchi, J | 1 |
| Mahdavi, R | 1 |
| Aliasgarzadeh, A | 1 |
| Asadi, Y | 1 |
| Koushavar, H | 1 |
| Vahed Jabbari, M | 1 |
| Morano, S | 1 |
| Mandosi, E | 1 |
| Fallarino, M | 1 |
| Gatti, A | 1 |
| Tiberti, C | 1 |
| Sensi, M | 1 |
| Gandini, L | 1 |
| Buchetti, B | 1 |
| Lenti, L | 1 |
| Jannini, EA | 1 |
| Lenzi, A | 1 |
| Salonia, A | 1 |
| Pickard, R | 1 |
| Ferland, A | 1 |
| Broderick, TL | 1 |
| Nadeau, A | 1 |
| Simard, S | 1 |
| Martin, J | 1 |
| Poirier, P | 1 |
| Cha, YS | 1 |
| Messano, M | 1 |
| Pregant, P | 2 |
| Kaiser, E | 2 |
| Schernthaner, G | 2 |
| Inokuchi, T | 1 |
| Imamura, K | 1 |
| Nomura, K | 1 |
| Nomoto, K | 1 |
| Isogai, S | 1 |
| Silvestre-Aillaud, P | 1 |
| BenDahan, D | 1 |
| Paquis-Fluckinger, V | 1 |
| Pouget, J | 1 |
| Pelissier, JF | 1 |
| Desnuelle, C | 1 |
| Cozzone, PJ | 1 |
| Vialettes, B | 1 |
| Abbott, CA | 1 |
| Vileikyte, L | 1 |
| Williamson, S | 1 |
| Carrington, AL | 1 |
| Boulton, AJ | 1 |
| Reddi, AS | 1 |
| Moquete, M | 1 |
| Keshav, G | 1 |
| DeAngelis, B | 1 |
| Frank, O | 1 |
| Baker, H | 1 |
| Greco, AV | 1 |
| Capristo, E | 1 |
| Benedetti, G | 1 |
| Giancaterini, A | 1 |
| De Gaetano, A | 1 |
| Gasbarrini, G | 1 |
| Dellow, WJ | 1 |
| Chambers, ST | 1 |
| Lever, M | 1 |
| Lunt, H | 1 |
| Robson, RA | 1 |
| Savle, PS | 1 |
| Pande, SV | 1 |
| Lee, TS | 1 |
| Gandour, RD | 1 |
| Eckel, RH | 1 |
| Hanson, AS | 1 |
| Chen, AY | 1 |
| Berman, JN | 1 |
| Yost, TJ | 1 |
| Brass, EP | 1 |
| Capaldo, B | 1 |
| Napoli, R | 1 |
| Di Bonito, P | 1 |
| Albano, G | 1 |
| Saccà, L | 1 |
| Legenstein, E | 1 |
| Lienhart, L | 1 |
| Bruck, S | 1 |
| Schnack, C | 1 |
| Digiesi, V | 1 |
| Palchetti, R | 1 |
| Cantini, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renoprotection in Early Diabetic Nephropathy in Pima Indians[NCT00340678] | Phase 3 | 170 participants (Actual) | Interventional | 1995-08-31 | Completed | ||
| Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)[NCT00072995] | 811 participants | Interventional | 2003-09-30 | Completed | |||
| Longitudinal Profiling of Gut Microbiome in Overweight or Obese Participants on a Modified Atkins Diet: a Prospective Cohort Study[NCT04207879] | 75 participants (Actual) | Observational | 2020-01-01 | Active, not recruiting | |||
| A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography[NCT00354081] | Phase 3 | 3,096 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy[NCT01967030] | 1,035 participants (Actual) | Observational | 2008-05-31 | Active, not recruiting | |||
| A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.[NCT02342340] | 8 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Exercise-mediated Rescue of Mitochondrial Derangements Driving Insulin Resistance in Humans (EX-MITO-DYS-IR)[NCT06080594] | 15 participants (Anticipated) | Interventional | 2024-02-29 | Recruiting | |||
| Mitochondrial Derangements Driving Muscle Insulin Resistance in Humans[NCT06080581] | 30 participants (Anticipated) | Observational | 2023-10-20 | Recruiting | |||
| Bioenergetics and Metabolism in Pediatric Populations[NCT03323294] | 175 participants (Anticipated) | Observational | 2017-10-18 | Active, not recruiting | |||
| Evaluation of a Bakery Product Enriched With Fibre and L-carnitine on Cardiovascular Risk Parameters in Patients With Metabolic Syndrome: a Randomized, Double-blind, Placebo-controlled Study[NCT02281253] | 54 participants (Actual) | Interventional | 2010-04-30 | Completed | |||
| Effects of Almond Consumption on Cardiovascular, Metabolomic, and Microbiome Profiles in Millennials: Implications of Systemic Glucoregulatory Mechanisms[NCT03084003] | 74 participants (Actual) | Interventional | 2016-02-18 | Completed | |||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| LIFESTAT - Living With Statins, a Cross Sectional Study on the Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being[NCT02250677] | 75 participants (Actual) | Observational | 2014-04-30 | Completed | |||
| Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being[NCT02796378] | Phase 4 | 30 participants (Anticipated) | Interventional | 2016-06-30 | Active, not recruiting | ||
| Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being[NCT02255682] | Phase 4 | 35 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Evidence-Based Approach to Dietary Management of Prader-Willi Syndrome (PWS)[NCT02011360] | 10 participants (Actual) | Interventional | 2014-05-31 | Completed | |||
| Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss II (MIPS II)[NCT02269410] | 6 participants (Actual) | Interventional | 2014-11-30 | Completed | |||
| Identification of Metabolic Phenotypes in Childhood Obesity by 1H-NMR Metabolomics of Blood Plasma[NCT03014856] | 102 participants (Actual) | Observational | 2012-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00340678)
Timeframe: 6 years after first treatment
| Intervention | *10^6 cubic microns (Mean) |
|---|---|
| Normoalbuminuria Losartan | 5.4 |
| Normoalbuminuria Placebo | 5.6 |
| Microalbuminuria Losartan | 6.4 |
| Microalbuminuria Placebo | 7.0 |
Participants were monitored for up to 6 years. This is the number of participants who had a decline in GFR to less than or equal to 60 ml/min or to half the baseline value in subjects that enter the study with a GFR of less than 120 ml/min during the time of observation. (NCT00340678)
Timeframe: Up to 6 years
| Intervention | participants (Number) |
|---|---|
| Normoalbuminuria Losartan | 2 |
| Normoalbuminuria Placebo | 2 |
| Microalbuminuria Losartan | 1 |
| Microalbuminuria Placebo | 4 |
14 reviews available for carnitine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Aging-Related Disorders and Mitochondrial Dysfunction: A Critical Review for Prospect Mitoprotective Strategies Based on Mitochondrial Nutrient Mixtures.
Topics: Aging; Animals; Antioxidants; Cardiovascular Diseases; Carnitine; Cell Line; Diabetes Mellitus, Type | 2020 |
Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients.
Topics: Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Dietary Supplements; Glycated Hemoglobin; Glyce | 2021 |
Do diabetes and obesity affect the metabolic response to exercise?
Topics: AMP-Activated Protein Kinases; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Exercise; Fatty | 2017 |
Role of carnitine and its derivatives in the development and management of type 2 diabetes.
Topics: Animals; Antioxidants; Carnitine; Diabetes Mellitus, Type 2; Dietary Supplements; Humans; Insulin Re | 2018 |
Metabolic effects of L-carnitine on type 2 diabetes mellitus: systematic review and meta-analysis.
Topics: Apolipoprotein A-I; Apolipoprotein B-100; Blood Glucose; Carnitine; Cholesterol; Diabetes Mellitus, | 2013 |
Metabolomics in diabetes, a review.
Topics: Amino Acids, Branched-Chain; Animals; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Humans; Insu | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Skeletal muscle mitochondria as a target to prevent or treat type 2 diabetes mellitus.
Topics: Caloric Restriction; Carnitine; Circadian Rhythm; Cryotherapy; Diabetes Mellitus, Type 2; Diet Thera | 2016 |
Carnitine and type 2 diabetes.
Topics: Acyl Coenzyme A; Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Die | 2009 |
Antioxidants in the treatment of diabetes.
Topics: Antioxidants; Ascorbic Acid; Carnitine; Clinical Trials as Topic; Diabetes Complications; Diabetes M | 2011 |
Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.
Topics: Acetylcarnitine; Animals; Cardiovascular Agents; Cardiovascular Diseases; Carnitine; Diabetes Mellit | 2011 |
Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency.
Topics: Acetyl Coenzyme A; Animals; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Dietary Supplements | 2012 |
Carnitine in type 2 diabetes.
Topics: Carnitine; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Lipid Metabolism; Organic Cation T | 2004 |
Effects of L-carnitine on obesity, diabetes, and as an ergogenic aid.
Topics: 3T3-L1 Cells; Animals; Carnitine; Cell Differentiation; Diabetes Mellitus, Type 2; Exercise; Humans; | 2008 |
33 trials available for carnitine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Plasma acylcarnitines and risk of incident heart failure and atrial fibrillation: the Prevención con dieta mediterránea study.
Topics: Atrial Fibrillation; Cardiovascular Diseases; Carnitine; Diabetes Mellitus, Type 2; Diet, Mediterran | 2022 |
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease.
Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter | 2022 |
Efficacy and Safety of the Combination of Superoxide Dismutase, Alpha Lipoic Acid, Vitamin B12, and Carnitine for 12 Months in Patients with Diabetic Neuropathy.
Topics: Aged; Carnitine; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Drug Combina | 2020 |
Plasma Palmitoyl-Carnitine (AC16:0) Is a Marker of Increased Postprandial Nonesterified Incomplete Fatty Acid Oxidation Rate in Adults With Type 2 Diabetes.
Topics: Adult; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Fasting; Fatty Acids, Nonesterified; Female | 2018 |
Changes in Gut Microbiota-Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial.
Topics: Adipose Tissue, White; Adiposity; Adult; Body Weight; Caloric Restriction; Carnitine; Choline; Diabe | 2018 |
Changes in Gut Microbiota-Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial.
Topics: Adipose Tissue, White; Adiposity; Adult; Body Weight; Caloric Restriction; Carnitine; Choline; Diabe | 2018 |
Changes in Gut Microbiota-Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial.
Topics: Adipose Tissue, White; Adiposity; Adult; Body Weight; Caloric Restriction; Carnitine; Choline; Diabe | 2018 |
Changes in Gut Microbiota-Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial.
Topics: Adipose Tissue, White; Adiposity; Adult; Body Weight; Caloric Restriction; Carnitine; Choline; Diabe | 2018 |
Family history and obesity in youth, their effect on acylcarnitine/aminoacids metabolomics and non-alcoholic fatty liver disease (NAFLD). Structural equation modeling approach.
Topics: Adolescent; Adult; Amino Acids; Carnitine; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Femal | 2018 |
Effect of metformin on plasma metabolite profile in the Copenhagen Insulin and Metformin Therapy (CIMT) trial.
Topics: Aged; Carnitine; Chromatography, Liquid; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glyca | 2018 |
Circulating Gut Microbiota Metabolite Trimethylamine N-Oxide (TMAO) and Changes in Bone Density in Response to Weight Loss Diets: The POUNDS Lost Trial.
Topics: Absorptiometry, Photon; Adult; Bone Density; Carnitine; Choline; Diabetes Mellitus, Type 2; Diet, Re | 2019 |
Improvement of Nonalcoholic Fatty Liver Disease With Carnitine-Orotate Complex in Type 2 Diabetes (CORONA): A Randomized Controlled Trial.
Topics: Alanine Transaminase; Anthropometry; Blood Glucose; Capsules; Carnitine; Diabetes Mellitus, Type 2; | 2015 |
Type 2 diabetes is associated with postprandial amino acid measures.
Topics: Adult; Amino Acids; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resist | 2016 |
Assessment of plasma acylcarnitines before and after weight loss in obese subjects.
Topics: Adult; Anthropometry; Body Composition; Carnitine; Diabetes Mellitus, Type 2; Fatty Acids; Fatty Aci | 2016 |
Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients.
Topics: Administration, Oral; Adult; Blood Glucose; Body Mass Index; Carnitine; Diabetes Mellitus, Type 2; D | 2008 |
L-Carnitine supplementation reduces oxidized LDL cholesterol in patients with diabetes.
Topics: Apolipoprotein A-I; Apolipoprotein B-100; Blood Glucose; Body Mass Index; Carnitine; Cholesterol; Ch | 2009 |
Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin.
Topics: Adult; Aged; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Human | 2009 |
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Topics: Apoprotein(a); Blood Glucose; Body Mass Index; Carnitine; Cholesterol, HDL; Cholesterol, LDL; Diabet | 2009 |
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
Topics: Aged; Appetite Depressants; Blood Glucose; Body Weight; C-Reactive Protein; Carnitine; Cholesterol; | 2011 |
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
Topics: Anti-Obesity Agents; Body Weight; Carnitine; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy | 2010 |
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
Topics: Blood Glucose; Carnitine; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2010 |
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
Topics: Adiponectin; Anti-Inflammatory Agents; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Wei | 2011 |
Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss.
Topics: Adult; Amino Acids, Branched-Chain; Carnitine; Cohort Studies; Diabetes Mellitus, Type 2; Female; Ga | 2011 |
Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss.
Topics: Adult; Amino Acids, Branched-Chain; Carnitine; Cohort Studies; Diabetes Mellitus, Type 2; Female; Ga | 2011 |
Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss.
Topics: Adult; Amino Acids, Branched-Chain; Carnitine; Cohort Studies; Diabetes Mellitus, Type 2; Female; Ga | 2011 |
Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss.
Topics: Adult; Amino Acids, Branched-Chain; Carnitine; Cohort Studies; Diabetes Mellitus, Type 2; Female; Ga | 2011 |
Levo-carnitine reduces oxidative stress and improves contractile functions of fast muscles in type 2 diabetic rats.
Topics: Animals; Carnitine; Diabetes Mellitus, Type 2; Malondialdehyde; Muscle Contraction; Muscle Fatigue; | 2013 |
The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hyperchole | 2003 |
Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial.
Topics: Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Female; Humans; Injections, Intravenous; Male; | 2004 |
Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus.
Topics: Apolipoproteins; Blood Glucose; Carnitine; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Meth | 2005 |
Propionyl-L-carnitine improves hemodynamics and metabolic markers of cardiac perfusion during coronary surgery in diabetic patients.
Topics: Aged; Blood Pressure; Cardiopulmonary Bypass; Cardiotonic Agents; Carnitine; Diabetes Mellitus, Type | 2005 |
Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
Topics: Aged; Apolipoproteins B; Carnitine; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combinatio | 2006 |
Effect of PLC on functional parameters and oxidative profile in type 2 diabetes-associated PAD.
Topics: Aged; Aldehydes; Ankle; Blood Glucose; Blood Pressure; Brachial Artery; Carnitine; Cholesterol, LDL; | 2006 |
Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study.
Topics: Aged; Antioxidants; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Ther | 2007 |
Evaluation of the efficacy of propionyl-L-carnitine versus pulsed muscular compressions in diabetic and non-diabetic patients affected by obliterating arteriopathy Leriche stage II.
Topics: Aged; Arterial Occlusive Diseases; Cardiovascular Agents; Carnitine; Combined Modality Therapy; Diab | 2008 |
No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Longitudinal Stu | 1993 |
Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration.
Topics: Adult; Aged; Canada; Carnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Foot; | 1998 |
L-carnitine improves glucose disposal in type 2 diabetic patients.
Topics: Analysis of Variance; Anthropometry; Basal Metabolism; Carnitine; Diabetes Mellitus, Type 2; Female; | 1999 |
[The benefits of L-carnitine therapy in essential arterial hypertension with diabetes mellitus type II].
Topics: Aged; Arrhythmias, Cardiac; Blood Pressure; Carnitine; Clinical Trials as Topic; Diabetes Mellitus, | 1989 |
91 other studies available for carnitine and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Impaired beta-oxidation increases vulnerability to influenza A infection.
Topics: Amino Acids, Branched-Chain; Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 2021 |
Medium & long-chain acylcarnitine's relation to lipid metabolism as potential predictors for diabetic cardiomyopathy: a metabolomic study.
Topics: Adult; Aminoimidazole Carboxamide; Animals; Biomarkers; Carnitine; Cell Line; Diabetes Mellitus, Typ | 2021 |
Correlation between Acylcarnitine and Peripheral Neuropathy in Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Body Mass Index; Carnitine; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; | 2022 |
Relationship Between Acylcarnitine and the Risk of Retinopathy in Type 2 Diabetes Mellitus.
Topics: Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; ROC Curve | 2022 |
Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort.
Topics: Aged; Betaine; Biomarkers; Carnitine; Choline; Cohort Studies; Cysteine; Diabetes Mellitus, Type 2; | 2022 |
Determinants of blood acylcarnitine concentrations in healthy individuals of the European Prospective Investigation into Cancer and Nutrition.
Topics: Carnitine; Diabetes Mellitus, Type 2; Fatty Acids; Humans; Neoplasms; Prospective Studies | 2022 |
Carnitine deficiency, hearing loss and hydrochlorothiazide-induced diabetes mellitus associated with the recurrent p.Trp85Arg variant in HNF4A.
Topics: Cardiomyopathies; Carnitine; Diabetes Mellitus, Type 2; Hearing Loss; Hepatocyte Nuclear Factor 4; H | 2022 |
L-carnitine, a friend or foe for cardiovascular disease? A Mendelian randomization study.
Topics: Cardiovascular Diseases; Carnitine; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Geno | 2022 |
Metabolomic comparison followed by cross-validation of enzyme-linked immunosorbent assay to reveal potential biomarkers of diabetic retinopathy in Chinese with type 2 diabetes.
Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Chenodeoxycholic Acid; China; Citrulline; Diabete | 2022 |
Beneficial Effects of Essential Oils from the Mediterranean Diet on Gut Microbiota and Their Metabolites in Ischemic Heart Disease and Type-2 Diabetes Mellitus.
Topics: Animals; Carnitine; Diabetes Mellitus, Type 2; Diet, Mediterranean; Emulsions; Fatty Acids, Volatile | 2022 |
Identification of Differential Metabolites Between
Type 2 Diabetes and Postchronic Pancreatitis Diabetes (Type 3c) Based on an Untargeted Metabolomics Approach.
Topics: Bile Acids and Salts; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Humans; Lipids; Pancreatitis | 2023 |
The association between acylcarnitine and amino acids profile and metabolic syndrome and its components in Iranian adults: Data from STEPs 2016.
Topics: Adult; Carnitine; Chromatography, Liquid; Citrulline; Cross-Sectional Studies; Diabetes Mellitus, Ty | 2023 |
Unsupervised cluster analysis of clinical and metabolite characteristics in patients with chronic complications of T2DM: an observational study of real data.
Topics: Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Humans; Insulin; Risk Factors | 2023 |
Metabolomics and Lipidomics Profiling Reveals Hypocholesterolemic and Hypolipidemic Effects of Arabinoxylan on Type 2 Diabetic Rats.
Topics: Amino Acids, Branched-Chain; Animals; Anticholesteremic Agents; Bile Acids and Salts; Carnitine; Dia | 2019 |
Purine Metabolites and Carnitine Biosynthesis Intermediates Are Biomarkers for Incident Type 2 Diabetes.
Topics: Aged; Aged, 80 and over; Biomarkers; Carnitine; Case-Control Studies; Chromatography, Liquid; Cohort | 2019 |
Plasma metabolomics in tuberculosis patients with and without concurrent type 2 diabetes at diagnosis and during antibiotic treatment.
Topics: Adult; Amines; Anti-Bacterial Agents; Blood Proteins; Body Weight; Carnitine; Chromatography, Liquid | 2019 |
Targeted Metabolomics Analysis Reveals that Dietary Supranutritional Selenium Regulates Sugar and Acylcarnitine Metabolism Homeostasis in Pig Liver.
Topics: Animals; Carnitine; Diabetes Mellitus, Type 2; Diet; Dietary Supplements; Dose-Response Relationship | 2020 |
Contributions of amino acid, acylcarnitine and sphingolipid profiles to type 2 diabetes risk among South-Asian Surinamese and Dutch adults.
Topics: Adult; Amino Acids; Carnitine; Diabetes Mellitus, Type 2; Ethnicity; Humans; Netherlands; Sphingolip | 2020 |
The Association Between Acylcarnitine Metabolites and Cardiovascular Disease in Chinese Patients With Type 2 Diabetes Mellitus.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Carnitine; Cross-Sectional Studies; Diabetes Mellitus, Ty | 2020 |
Metabolic Effects of Gastric Bypass Surgery: Is It All About Calories?
Topics: Adult; Blood Glucose; Caloric Restriction; Carnitine; Diabetes Mellitus, Type 2; Fasting; Female; Ga | 2020 |
Serum acylcarnitines and amino acids and risk of type 2 diabetes in a multiethnic Asian population.
Topics: Amino Acids; Carnitine; Diabetes Mellitus, Type 2; Female; Humans; Male; Prospective Studies; Risk F | 2020 |
Non-targeted urine metabolomics and associations with prevalent and incident type 2 diabetes.
Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Chromatography, Liquid; Diabetes Mellitus, Type 2 | 2020 |
Association of cardiac autonomic dysfunction with higher levels of plasma lipid metabolites in recent-onset type 2 diabetes.
Topics: Adult; Autonomic Nervous System Diseases; Carnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, T | 2021 |
Walnut Consumption, Plasma Metabolomics, and Risk of Type 2 Diabetes and Cardiovascular Disease.
Topics: Amino Acids; Biomarkers; Cardiovascular Diseases; Carnitine; Diabetes Mellitus, Type 2; Humans; Jugl | 2021 |
Metabolites that activate the inflammasome in nascent metabolic syndrome.
Topics: Adult; Carnitine; Caspase 1; Diabetes Mellitus, Type 2; gamma-Aminobutyric Acid; Humans; Inflammasom | 2021 |
Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications.
Topics: Amino Acids; Carnitine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Metabolomics; Pred | 2021 |
Triangulating evidence from longitudinal and Mendelian randomization studies of metabolomic biomarkers for type 2 diabetes.
Topics: Adult; Aged; Betaine; Biomarkers; Carnitine; Case-Control Studies; Diabetes Mellitus, Type 2; Early | 2021 |
Metabolomics Profiling of Patients With A-β+ Ketosis-Prone Diabetes During Diabetic Ketoacidosis.
Topics: Adult; Amino Acids, Branched-Chain; Autoantibodies; Carnitine; Diabetes Mellitus, Type 1; Diabetes M | 2021 |
Carnitine Orotate Complex Ameliorates Insulin Resistance and Hepatic Steatosis Through Carnitine Acetyltransferase Pathway.
Topics: Animals; Body Weight; Carnitine; Carnitine O-Acetyltransferase; Diabetes Mellitus, Type 2; Humans; I | 2021 |
Diminished retinal complex lipid synthesis and impaired fatty acid β-oxidation associated with human diabetic retinopathy.
Topics: Adult; Aged; American Indian or Alaska Native; Arizona; Black or African American; Carnitine; Case-C | 2021 |
N-acyl Taurines and Acylcarnitines Cause an Imbalance in Insulin Synthesis and Secretion Provoking β Cell Dysfunction in Type 2 Diabetes.
Topics: Animals; Carnitine; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Secretion; Insulin-Secreting | 2017 |
Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris.
Topics: Aged; Angina, Stable; Betaine; Body Mass Index; Carnitine; Chromatography, Liquid; Coronary Artery D | 2018 |
Elevated Medium-Chain Acylcarnitines Are Associated With Gestational Diabetes Mellitus and Early Progression to Type 2 Diabetes and Induce Pancreatic β-Cell Dysfunction.
Topics: Adult; Animals; Carnitine; Case-Control Studies; Cell Respiration; Diabetes Mellitus, Type 2; Diabet | 2018 |
Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps.
Topics: Adult; Aged; Carnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypogl | 2018 |
Glucose challenge metabolomics implicates medium-chain acylcarnitines in insulin resistance.
Topics: 3T3-L1 Cells; Aged; Animals; Carnitine; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; | 2018 |
Assessing the Levels of L-Carnitine and Total Antioxidant Capacity in Adults With Newly Diagnosed and Long-Standing Type 2 Diabetes.
Topics: Adult; Aged; Antioxidants; Biomarkers; Blood Glucose; Carnitine; Case-Control Studies; Cholesterol, | 2019 |
Letter to the Editor: "Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris".
Topics: Angina, Stable; Carnitine; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Risk Factors | 2018 |
Response to Letter to the Editor: "Serum Carnitine Metabolites and Incident Type 2 Diabetes Mellitus in Patients With Suspected Stable Angina Pectoris".
Topics: Angina, Stable; Carnitine; Diabetes Mellitus, Type 2; Humans; Myocardial Infarction; Risk Factors | 2018 |
Plasma Acylcarnitines and Risk of Type 2 Diabetes in a Mediterranean Population at High Cardiovascular Risk.
Topics: Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Carnitine; Case-Control Studies; Diabe | 2019 |
In-and-Out Molecular Changes Linked to the Type 2 Diabetes Remission after Bariatric Surgery: An Influence of Gut Microbes on Mitochondria Metabolism.
Topics: Adult; Amino Acids; Bariatric Surgery; Blood Glucose; Carnitine; Chromatography, Liquid; Diabetes Me | 2018 |
Intra- and inter-individual metabolic profiling highlights carnitine and lysophosphatidylcholine pathways as key molecular defects in type 2 diabetes.
Topics: Aged; Biomarkers; Carnitine; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Insuli | 2019 |
Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy.
Topics: Aged; Aged, 80 and over; Arginine; Biomarkers; Carnitine; Case-Control Studies; Chromatography, Liqu | 2019 |
Fatty Acid Metabolites Combine with Reduced β Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes.
Topics: Adult; Aged; Carnitine; Carnitine O-Palmitoyltransferase; Cells, Cultured; Cross-Sectional Studies; | 2019 |
Variation of serum metabolites related to habitual diet: a targeted metabolomic approach in EPIC-Potsdam.
Topics: Adult; Amino Acids; Carnitine; Chronic Disease; Cross-Sectional Studies; Diabetes Mellitus, Type 2; | 2013 |
Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease.
Topics: Aged; Aged, 80 and over; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carnitine; Carotid Steno | 2013 |
Serum levels of acylcarnitines are altered in prediabetic conditions.
Topics: Adult; Aged; Blood Glucose; Body Composition; Carnitine; Diabetes Mellitus, Type 2; Female; Glucose | 2013 |
Early mitochondrial dysfunction in glycolytic muscle, but not oxidative muscle, of the fructose-fed insulin-resistant rat.
Topics: Aconitate Hydratase; Animals; Carnitine; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Disease P | 2014 |
Acylcarnitines activate proinflammatory signaling pathways.
Topics: Animals; Carnitine; Cell Line, Transformed; Cell Line, Tumor; Cyclooxygenase 2; Cytokines; Diabetes | 2014 |
Human serum acylcarnitine profiles in different glucose tolerance states.
Topics: Biomarkers; Blood Glucose; Carnitine; Chromatography, Liquid; Diabetes Mellitus, Type 2; Fasting; Fe | 2014 |
Evidence that multiple defects in lipid regulation occur before hyperglycemia during the prodrome of type-2 diabetes.
Topics: Adiponectin; Adipose Tissue; Adult; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Diabetes, G | 2014 |
Pioglitazone treatment restores in vivo muscle oxidative capacity in a rat model of diabetes.
Topics: Animals; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Hypertriglyceridemia; Hypoglycemic Agents | 2015 |
Urinary F2-isoprostanes and metabolic markers of fat oxidation.
Topics: Carnitine; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Diabetes Mellitus, Type 2; | 2015 |
The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions.
Topics: Animals; Brain; Cardiovascular Diseases; Carnitine; Carnitine O-Palmitoyltransferase; Ceramides; Dia | 2015 |
Effect of a β-Hydroxyphosphonate Analogue of ʟ-Carnitine on Insulin-Sensitive and Insulin-Resistant 3T3-L1 Adipocytes.
Topics: 3T3-L1 Cells; 4-Chloro-7-nitrobenzofurazan; Adipocytes; Adipogenesis; Animals; Carnitine; Cell Diffe | 2015 |
Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in Type 2 diabetic rats.
Topics: Animals; Antioxidants; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, | 2016 |
Hemodialysis Associated with Severe and Unpredictable Hypoglycemia.
Topics: Aged; Autopsy; Blood Glucose; Cardiomyopathies; Carnitine; Diabetes Mellitus, Type 2; Fatal Outcome; | 2016 |
Metabolomics Study of Roux-en-Y Gastric Bypass Surgery (RYGB) to Treat Type 2 Diabetes Patients Based on Ultraperformance Liquid Chromatography-Mass Spectrometry.
Topics: Adult; Amino Acids; Bile Acids and Salts; Bilirubin; Biomarkers; Carnitine; Chromatography, High Pre | 2016 |
Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery.
Topics: Adult; Atherosclerosis; Bariatric Surgery; Betaine; Body Mass Index; Cardiovascular Diseases; Carnit | 2016 |
Untargeted mass spectrometric approach in metabolic healthy offspring of patients with type 2 diabetes reveals medium-chain acylcarnitine as potential biomarker for lipid induced glucose intolerance (LGIT).
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Carnitine; Case-Control Studies; Chromatography, | 2016 |
Early Prediction of Developing Type 2 Diabetes by Plasma Acylcarnitines: A Population-Based Study.
Topics: Aged; Biomarkers; Blood Glucose; Carnitine; China; Chromatography, Liquid; Diabetes Mellitus, Type 2 | 2016 |
Palmitoyl-carnitine production by blood cells associates with the concentration of circulating acyl-carnitines in healthy overweight women.
Topics: Adult; Aged; Blood Cells; Blood Glucose; Body Mass Index; Carnitine; Diabetes Mellitus, Type 2; Fema | 2017 |
Plasma acylcarnitine profiling indicates increased fatty acid oxidation relative to tricarboxylic acid cycle capacity in young, healthy low birth weight men.
Topics: Adult; Birth Weight; Carnitine; Citric Acid Cycle; Cross-Over Studies; Denmark; Diabetes Mellitus, T | 2016 |
Acylcarnitines as markers of exercise-associated fuel partitioning, xenometabolism, and potential signals to muscle afferent neurons.
Topics: Adenosine Triphosphate; Adult; Amino Acids, Branched-Chain; Biomarkers; Carnitine; Citric Acid Cycle | 2017 |
Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women.
Topics: Adult; Aged; Aged, 80 and over; Black or African American; Carnitine; Citric Acid Cycle; Diabetes Me | 2009 |
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Carnitin | 2009 |
Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity.
Topics: Adult; Biomarkers; Body Mass Index; Carnitine; Diabetes Mellitus, Type 2; Fasting; Glucose Clamp Tec | 2010 |
Aminocarnitine ureidic derivatives as inhibitors of carnitine palmitoyltransferase I.
Topics: Animals; Betaine; Binding Sites; Carnitine; Carnitine O-Palmitoyltransferase; Computer Simulation; D | 2010 |
Inspiratory muscle strength is correlated with carnitine levels in type 2 diabetes.
Topics: Blood Glucose; Carnitine; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Male; Mid | 2010 |
Rehabilitative treatment in peripheral artery disease: protocol application and follow-up.
Topics: Aged; Cardiotonic Agents; Carnitine; Clinical Protocols; Combined Modality Therapy; Diabetes Mellitu | 2010 |
[Low L-carnitine levels: can it be a cause of nocturnal blood pressure changes in patients with type 2 diabetes mellitus?].
Topics: Aged; Blood Pressure; Carnitine; Case-Control Studies; Circadian Rhythm; Cohort Studies; Cross-Secti | 2011 |
Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis.
Topics: Analysis of Variance; Animals; Area Under Curve; Carnitine; Carnitine O-Palmitoyltransferase; Diabet | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Increased mitochondrial substrate sensitivity in skeletal muscle of patients with type 2 diabetes.
Topics: Carnitine; Case-Control Studies; Cell Respiration; Citrate (si)-Synthase; Diabetes Mellitus, Type 2; | 2011 |
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; E | 2011 |
Metabolomic profiling of fatty acid and amino acid metabolism in youth with obesity and type 2 diabetes: evidence for enhanced mitochondrial oxidation.
Topics: Absorptiometry, Photon; Adolescent; Amino Acids; Carnitine; Diabetes Mellitus, Type 2; Fasting; Fatt | 2012 |
High L-carnitine concentrations do not prevent late diabetic complications in type 1 and 2 diabetic patients.
Topics: Adult; Aged; Carnitine; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | 2012 |
Consumption of a high β-glucan barley flour improves glucose control and fatty liver and increases muscle acylcarnitines in the Zucker diabetic fatty rat.
Topics: Adiponectin; Animals; beta-Glucans; Blood Glucose; Body Weight; Carnitine; Cholesterol; Diabetes Mel | 2013 |
Similarities in serum acylcarnitine patterns in type 1 and type 2 diabetes mellitus and in metabolic syndrome.
Topics: Adult; Aged; Body Mass Index; Carnitine; Case-Control Studies; Diabetes Mellitus, Type 1; Diabetes M | 2013 |
Serum levo-carnitine levels and skeletal muscle functions in type 2 diabetes mellitus in rodents.
Topics: Animals; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Elec | 2013 |
Effect of L-carnitine on acetyl-CoA content and activity of blood platelets in healthy and diabetic persons.
Topics: Acetyl Coenzyme A; Adult; Blood Platelets; Carnitine; Diabetes Mellitus, Type 1; Diabetes Mellitus, | 2005 |
Determination of free L-carnitine levels in type II diabetic women with and without complications.
Topics: Blood Glucose; Blood Pressure; Body Mass Index; Carnitine; Case-Control Studies; Cross-Sectional Stu | 2007 |
Editorial comment on: Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study.
Topics: Antioxidants; Carnitine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erectile Dysfunction; | 2007 |
Editorial comment on: Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study.
Topics: Antioxidants; Carnitine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Erectile Dysfunction; | 2007 |
Impact of fasting and postprandial state on plasma carnitine concentrations during aerobic exercise in type 2 diabetes.
Topics: Aerobiosis; Body Mass Index; Carnitine; Diabetes Mellitus, Type 2; Exercise; Fasting; Fatty Acids, N | 2007 |
Changes in carnitine metabolism with ketone body production in obese glucose-intolerant patients.
Topics: Acylation; Adult; Blood Glucose; Carnitine; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose In | 1995 |
Could coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA?
Topics: Blood Glucose; C-Peptide; Carnitine; Coenzymes; Deafness; Diabetes Mellitus, Type 2; DNA, Mitochondr | 1995 |
Plasma carnitine levels in patients undergoing hemodialysis.
Topics: Adult; Biomarkers; Carnitine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Kid | 1998 |
Elevated glycine betaine excretion in diabetes mellitus patients is associated with proximal tubular dysfunction and hyperglycemia.
Topics: Adult; Aged; Aged, 80 and over; Alkaloids; Betaine; Biomarkers; Carnitine; Creatinine; Diabetes Mell | 1999 |
Stereoisomeric acylamidomorpholinium carnitine analogues: selective inhibitors of carnitine palmitoyltransferase I and II.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Diabetes Mellitus, Type 2; Drug Design; Enzyme | 1999 |
Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adult; Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; F | 1992 |
Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients.
Topics: Blood Glucose; Carnitine; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose; Hu | 1991 |
[Decreased plasma carnitine in Type I diabetes mellitus].
Topics: Adult; Blood Glucose; Carnitine; Circadian Rhythm; Diabetes Mellitus, Type 1; Diabetes Mellitus, Typ | 1991 |